Page last updated: 2024-11-04

diazoxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Diazoxide is a potassium channel opener that is used to treat hypoglycemia in patients with hyperinsulinism. It is also used as an antihypertensive agent. Diazoxide is synthesized by reacting diazotized 2-amino-5-chlorobenzophenone with sodium 4-hydroxy-2-nitrobenzoate. Diazoxide acts by opening potassium channels in pancreatic beta cells, thereby inhibiting insulin secretion. It is also known to relax smooth muscle, which is the mechanism by which it lowers blood pressure. Diazoxide is studied to understand its effects on other potassium channels, such as those involved in the nervous system and heart. Researchers are also exploring its potential use in treating other conditions, such as diabetes and epilepsy.'

Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3019
CHEMBL ID181
CHEMBL ID1518123
CHEBI ID4495
SCHEMBL ID41254
MeSH IDM0006242

Synonyms (220)

Synonym
7-chloro-3-methyl-2h-1,4-benzothiadiazine 1,1-dioxide
nsc-64198
nsc-76130
2h-1,4-benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
CBIOL_001750
MLS001076071
HMS3393P20
HMS3267I11
BRD-K73109821-001-05-2
7-chloro-3-methyl-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide
gtpl2409
mutabase
proglycem
nsc76130
proglicem
eudemine
7-chloro-3-methyl-2h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide
srg 95213
hypertonalum
nsc64198
2h-1,2, 4-benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
sch 6783
7-chloro-3-methyl-2h-1,2,4-benzothiadiazine 1,1-dioxide
dizoxide
hyperstat
7-chloro-3-methyl-1lambda~4~,2,4-benzothiadiazin-1-ol 1-oxide
srg-95213
aroglycem
sch-6783
EU-0100404
c8h7cln2o2s
nsc 76130
nsc 64198
2h-1,2,4-benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
einecs 206-668-1
diazossido [dcit]
7-cloro-3-metil-2h-1,2,4-benzotiodiazina-1,1-diossido [italian]
diazoxido [inn-spanish]
diazossido [italian]
diazoxidum [inn-latin]
IDI1_033777
PRESTWICK_163
BIO1_000525
BIO2_000507
NCGC00015380-02
NCGC00024907-01
tocris-0964
NCGC00015380-01
cas-364-98-7
BIO1_000036
BIO1_001014
lopac-d-9035
BIO2_000027
PRESTWICK2_000087
PRESTWICK3_000087
BSPBIO_002290
BSPBIO_000014
BPBIO1_000016
LOPAC0_000404
CHEBI:4495 ,
diazoxido
diazoxidum
diazossido
diazoxide
364-98-7
C06949
DB01119
D00294
proglycem (tn)
hyperstat (tn)
diazoxide (jan/usp/inn)
BSPBIO_001307
NCGC00024907-04
NCGC00024907-03
NCGC00024907-07
NCGC00024907-06
MLS000028459 ,
smr000058392
KBIO2_005163
KBIO3_000053
KBIOGR_001776
KBIO3_001510
KBIOSS_000027
KBIO2_000027
KBIO2_002595
KBIO3_000054
KBIOGR_000027
PRESTWICK0_000087
SPECTRUM3_000735
SPBIO_001953
PRESTWICK1_000087
SPECTRUM4_001248
SPECTRUM2300206
NCGC00024907-05
NCGC00015380-03
NCGC00024907-08
NCGC00024907-02
NCGC00015380-05
HMS2093N12
HMS2051P20
HMS2089L04
D 9035 ,
HMS1989B09
NCGC00015380-12
VU0239714-6
CHEMBL181
eudemine injection
HMS1361B09
HMS1791B09
HMS1922L22
HMS1568A16
NCGC00015380-09
HMS2095A16
HMS3261A10
o5cb12l4fn ,
diazoxide [usan:usp:inn:ban:jan]
7-cloro-3-metil-2h-1,2,4-benzotiodiazina-1,1-diossido
unii-o5cb12l4fn
A823275
3-methyl-7-chloro-1,2,4-benzothiadiazine 1,1-dioxide
pharmakon1600-02300206
MLS001424164
nsc-759574
nsc759574
tox21_110132
dtxsid7022914 ,
dtxcid902914
CCG-204497
cas_364-98-7
bdbm86248
nsc_3019
HMS2234B23
S4630
CCG-101062
NCGC00015380-10
NCGC00015380-08
NCGC00015380-13
NCGC00015380-11
NCGC00015380-06
NCGC00015380-04
NCGC00015380-07
FT-0603087
LP00404
AKOS015896340
HMS3371L13
diazoxide [inn]
diazoxide [who-ip]
diazoxide [vandf]
diazoxide [orange book]
diazoxide [mart.]
diazoxide [usan]
diazoxide [usp-rs]
diazoxide [jan]
diazoxide [ep monograph]
diazoxide [mi]
diazoxidum [who-ip latin]
diazoxide [usp monograph]
diazoxide [who-dd]
KC-115
NC00312
SCHEMBL41254
tox21_110132_1
NCGC00022882-03
7-chloro-3-methyl-4h-1$l^{6},2,4-benzothiadiazine 1,1-dioxide
NCGC00261089-01
CS-4745
tox21_500404
7-chloro-3-methyl-4h-1,2,4-benzothiadiazine 1,1-dioxide
4h-1,2,4-benzothiadiazine, 7-chloro-3-methyl-, 1,1-dioxide
HB0244
7-chloro-3-methyl-2h-1,2,4-benzothiadiazine1,1-dioxide
CHEMBL1518123
HY-B1140
AKOS024458715
HMS3402B09
OPERA_ID_608
mfcd00078578
eudimine
bdbm50237612
7-chloro-3-methyl-4h-1$l^{6},2,4-benzothiadiazine-1,1-dione
KS-1444
diazoxide, united states pharmacopeia (usp) reference standard
diazoxide, european pharmacopoeia (ep) reference standard
SR-01000075314-1
sr-01000075314
SR-01000075314-6
SR-01000075314-3
SR-01000075314-4
HMS3712A16
BCP26107
Q420009
Z1269122570
HMS3675L18
D5402
HMS3411L18
BRD-K73109821-001-10-2
7-chloro-3-methyl-4h-1lambda6,2,4-benzothiadiazine 1,1-dioxide
SDCCGSBI-0050390.P002
NCGC00015380-20
HMS3885H12
7-chloro-3-methyl-4h-1|e6,2,4-benzothiadiazine 1,1-dioxide
364-98-7 (free)
SY066792
F12855
3-methyl-7-chloro-1,2,4-benzothiadiazine1,1-dioxide
7-chloro-3-methyl-2h-benzo[e][1,2,4]thiadiazine 1,1-dioxide ,
diazoxide 100 microg/ml in acetonitrile
7-chloro-3-methyl-2h-1lambda6,2,4-benzothiadiazine-1,1-dione
EN300-122611
diazoxide (usan:usp:inn:ban:jan)
diazoxidum (inn-latin)
diazoxide (mart.)
c02da01
diazoxide (usp-rs)
v03ah01
diazoxide (ep monograph)
diazoxide oral solution
diazoxide oral suspension
diazoxido (inn-spanish)
diazoxide (usp monograph)

Research Excerpts

Overview

Diazoxide (DZ) is a highly selective mitochondrial adenosine triphosphate-sensitive potassium channel opener. Its effect on 5-hydroxyindole acetic acid (5-HIAA) and dopamine amines in adult animal models remains unclear.

ExcerptReferenceRelevance
"Diazoxide is a peripheral vasodilator that has been used for intravenous treatment of hypertensive emergencies. "( Cerebral Insufficiency Caused by Diazoxide in a Premature Neonate with Congenital Hyperinsulinism.
Fukunaga, S; Furuta, T; Hirano, R; Ishikawa, Y; Motonaga, T; Ohta, H; Okada, S, 2020
)
2.28
"Diazoxide (DZ) is a highly selective mitochondrial adenosine triphosphate-sensitive potassium channel opener."( Diazoxide Protects against Myocardial Ischemia/Reperfusion Injury by Moderating ERS via Regulation of the miR-10a/IRE1 Pathway.
Cai, S; Cao, S; Li, K; Nie, J; Wang, H; Yu, S; Yu, T; Zhang, L; Zhang, Y; Zhou, W, 2020
)
2.72
"Diazoxide is a drug used in the treatment of hypertension however, its effect on 5-hydroxyindole acetic acid (5-HIAA) and dopamine amines in adult animal models remains unclear."( Trace elements cause oxidative damage in the brain of rats with induced hypotension.
Brizuela, NO; Guzmán, DC; Herrera, MO; Mejía, GB; Olguín, HJ; Peraza, AV, 2017
)
1.18
"Diazoxide (DZ) is a pharmacological opener of ATP-sensitive K(+) channels that has been used for mimicking ischemic preconditioning and shows protection against ischemic damage. "( Diazoxide, a K(ATP) channel opener, prevents ischemia-reperfusion injury in rodent pancreatic islets.
Feng, F; Harvat, T; Kinzer, K; Oberholzer, J; Qi, M; Wang, S; Wang, Y; Zhang, L, 2015
)
3.3
"Diazoxide is an effective and usually safe medication to treat this type and other types of neonatal HI."( Liver injury may increase the risk of diazoxide toxicity: a case report.
Garibaldi, L; Mahmood, B; Sperling, M; Tas, E, 2015
)
1.41
"Diazoxide is a non-diuretic benzothiadiazine derivative, one of a group of substances introduced into clinical practice in the 1950s for the treatment of hypertension. "( Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia.
Inoue, Y; Komatsu, Y; Miyoshi, H; Nakamura, A; Tajima, K; Takano, T; Takihata, M; Terauchi, Y; Tsuchiya, H; Yahagi, S; Yamakawa, T; Yoshida, M, 2016
)
2.17
"Diazoxide is a first-line treatment of CHI with high safety. "( The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism.
Hu, S; Li, W; Liu, M; Sang, Y; Sun, B; Xu, Z; Yan, J, 2012
)
2.13
"Diazoxide is a benzothiadiazine derivative related to the thiazide diuretics and a potassium channel opener."( Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia.
Akhondzadeh, S; Amini-Nooshabadi, H; Kamalipour, A; Mirsepassi, GR; Moin, M; Mojtahedzadeh, V, 2002
)
2.48
"Diazoxide is an agonist of the pancreatic beta-cell KATP channel and inhibits insulin secretion."( Ketotic hypoglycaemia in children with diazoxide responsive hyperinsulinism of infancy.
Hussain, K, 2005
)
1.32
"Diazoxide is a selective mitochondria ATP-sensitive potassium (K(ATP)) channel opener, which has been reported to preserve the microvascular integrity of ischemia-reperfusion (I/R)-injured tissues. "( Diazoxide ameliorates microcirculatory disturbances through PKC-dependent pathway in I/R-injured rat cremaster muscles.
Hung, LM; Wei, FC; Wei, W, 2005
)
3.21
"Diazoxide is a putative mitochondrial, ATP-sensitive potassium channel opener that has been implicated in neuroprotection in cerebral ischemia. "( Post-ischemic administration of diazoxide attenuates long-term microglial activation in the rat brain after permanent carotid artery occlusion.
Bari, F; Domoki, F; Farkas, E; Luiten, PG; Mihály, A; Timmer, NM, 2005
)
2.05
"Diazoxide is a potent antihypertensive agent due to its peripheral vasodilator action. "( Effects of diazoxide on maternal and fetal circulations in normotensive and hypertensive pregnant sheep.
Kuijken, JP; Wallenburg, HC, 1984
)
2.1
"Diazoxide is a weak cardiac sarcolemmal KATP opener, but it is a potent opener of mitochondrial KATP, making it a useful tool for determining the importance of this mitochondrial site."( Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Possible mechanism of cardioprotection.
D'Alonzo, AJ; Darbenzio, RB; Garlid, KD; Grover, GJ; Lodge, NJ; Murray, HN; Paucek, P; Smith, MA; Yarov-Yarovoy, V, 1997
)
1.32
"Diazoxide is an efficient treatment in the long-term management of most persistent hyperinsulinaemic hypoglycaemia of infancy revealed in infants and children but is usually ineffective in neonatal forms. "( Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria.
Brunelle, F; Czernichow, P; Nihoul-Fekete, C; Ogier de Baulny, H; Poggi-Travert, F; Rahier, J; Saudubray, JM; Touati, G, 1998
)
1.97
"Diazoxide is a potent and safe antipressor agent for parenteral administration in hypertensive emergencies. "( Diazoxide for hypertensive crisis.
Vidt, DG, 1975
)
3.14
"Diazoxide appears to be a safe antihypertensive drug that is effective in the treatment of hypertension secondary to acute poststreptococcal glomerulonephritis."( Intravenous diazoxide in acute poststreptococcal glomerulonephritis.
Hill, LL; Kohaut, EC; Wilson, CJ, 1975
)
1.35

Effects

Diazoxide (DIAZ) has been shown to be neuroprotective in animal models of different brain pathologies. Diazoxide has the advantage compared with nitroprusside sodium that an intravenous injection decreases the blood pressure for several hours.

ExcerptReferenceRelevance
"Diazoxide (DZ) has been shown to induce ischemic tolerance."( Synergistic Reduction of Apoptosis With Diazoxide and Erythropoietin in Spinal Cord Ischemic Injury.
Aftab, M; Cleveland, JC; Eldeiry, M; Fullerton, DA; Mares, J; Meng, X; Reece, TB; Ryan, TJ; Weyant, MJ; Yamanaka, K, 2018
)
1.47
"Diazoxide has been identified over the past 50years to have a number of physiological effects, including lowering the blood pressure and rectifying hypoglycemia. "( Multiplicity of effectors of the cardioprotective agent, diazoxide.
Coetzee, WA, 2013
)
2.08
"Diazoxide has similar effects in CD34+ cells as described for muscle or nerve cells. "( The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a.
Körper, S; Nolte, F; Rojewski, MT; Schrezenmeier, H; Thiel, E, 2003
)
2.07
"Diazoxide has been shown to confer significant myocardial protection in many experiments. "( Diazoxide provides protection to human myocardium in vitro that is concentration dependent.
Biernat, J; Deja, MA; Golba, KS; Kolowca, M; Widenka, K; Wos, S, 2004
)
3.21
"Diazoxide has been identified as a mitochondrial, ATP-dependent K(+) channel opener, and a potentially neuroprotective compound under ischemic conditions. "( The effect of pre- and posttreatment with diazoxide on the early phase of chronic cerebral hypoperfusion in the rat.
Bari, F; Domoki, F; Farkas, E; Institóris, A; Mihály, A, 2006
)
2.04
"Diazoxide (DIAZ) has been shown to be neuroprotective in animal models of different brain pathologies. "( Diazoxide is protective in the rat retina against ischemic injury induced by bilateral carotid occlusion and glutamate-induced degeneration.
Atlasz, T; Babai, N; Bari, F; Domoki, F; Gabriel, R; Kiss, P; Reglodi, D; Tamas, A, 2007
)
3.23
"Diazoxide has the advantage compared with nitroprusside sodium that an intravenous injection decreases the blood pressure for several hours."( [Hypertensive crisis and its treatment].
de Châtel, R, 1980
)
0.98

Actions

Diazoxide did not increase the heart rate as much as expected (P greater than 0.10), while labetalol slowed it down moderately but significantly. Diazoxide could enhance liver regeneration by keeping a higher ATP content of the liver tissue.

ExcerptReferenceRelevance
"Diazoxide did not increase sarcolemmal adenosine triphosphate-sensitive potassium current in wild-type myocytes, although they demonstrated significant swelling during exposure to cardioplegia that was prevented by diazoxide. "( Diazoxide maintenance of myocyte volume and contractility during stress: evidence for a non-sarcolemmal K(ATP) channel location.
Al-Dadah, AS; Lawton, JS; Maffit, SK; Nichols, CG; Schuessler, RB; Sellitto, AD; Zhang, H, 2010
)
3.25
"Diazoxide could enhance liver regeneration by keeping a higher ATP content of the liver tissue."( Enhancement of liver regeneration by adenosine triphosphate-sensitive K⁺ channel opener (diazoxide) after partial hepatectomy.
Abe, Y; Nakagawa, Y; Ohba, T; Ono, K; Uchinami, H; Yamamoto, Y; Yoshioka, M, 2012
)
1.32
"Diazoxide did not increase reduced glutathione and manganese-superoxide dismutase levels but we found significantly higher reduced glutathione levels in diazoxide-pre-conditioned neurons after OGD."( Diazoxide induces delayed pre-conditioning in cultured rat cortical neurons.
Busija, DW; Horiguchi, T; Kis, B; Nagy, K; Rajapakse, NC; Snipes, JA, 2003
)
2.48
"Diazoxide did not cause mitochondrial oxidation or mitochondrial depolarisation, suggesting it induces protection via another mechanism."( FCCP is cardioprotective at concentrations that cause mitochondrial oxidation without detectable depolarisation.
Baghai, M; Berry, RG; Brennan, JP; Duchen, MR; Shattock, MJ, 2006
)
1.06
"Diazoxide prevented the increase in mitochondrial Ca(2+), mitochondrial depolarization and cytochrome c release induced by hypoxia and all these effects of diazoxide were blocked by epsilonV1-2 or 5-HD."( Diazoxide acts more as a PKC-epsilon activator, and indirectly activates the mitochondrial K(ATP) channel conferring cardioprotection against hypoxic injury.
Ahn, JH; Baik, EJ; Jung, YS; Kim, MJ; Kim, MY; Lee, SH; Moon, CH; Yoon, IS, 2006
)
2.5
"Diazoxide seems to inhibit only the entrance of calcium from outside the cell but does not seem to inhibit the entrance determined by theophylline and pentoxiphylline from intracellular compartments."( A comparative study of two insulin secretion inhibitors: somatostatin and diazoxide.
Aparicio, M; Basabe, JC; Cresto, JC; Fabiano de Bruno, L; Karabatas, L, 1982
)
1.22
"Diazoxide did not increase the heart rate as much as expected (P greater than 0.10), while labetalol slowed it down moderately but significantly (P less than 0.05)."( Diazoxide vs labetalol: a cross-over comparison of short-term effects in hypertension.
Bagatin, J; Rumboldt, Z; Vidovic, A, 1983
)
2.43
"Diazoxide does not inhibit the dehydrogenase in mitochondria from skeletal muscle, liver, and heart."( High content of mitochondrial glycerol-3-phosphate dehydrogenase in pancreatic islets and its inhibition by diazoxide.
MacDonald, MJ, 1981
)
1.2
"The diazoxide-induced increase in ROS also was abrogated by the addition of either the antioxidant N-acetylcysteine (NAC) or N-mercaptopropionylglycine."( Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism.
Forbes, RA; Murphy, E; Steenbergen, C, 2001
)
2.23
"The diazoxide-mediated increase in the forearm blood flow ratio (infused/control arm) was significantly less pronounced after glibenclamide than after acarbose (290 +/- 58% and 561 +/- 101% respectively; P<0.0005)."( Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
Abbink, EJ; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ; van Rosendaal, AJ, 2002
)
0.8
"Diazoxide caused no increase in heart rate after combined beta-adrenoreceptor and parasympathetic blockade."( Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension.
Man in 't Veld, AJ; Schalekamp, MA; Verhoeven, RP; Wenting, GJ, 1978
)
0.98
"Diazoxide caused an increase in 86Rb+ efflux from the rat aorta and portal vein and inhibited spontaneous activity of the latter at concentrations 100 times higher than the K+ channel opener cromakalim. "( In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.
Cook, NS; Quast, U, 1989
)
1.96
"Diazoxide appears to cause post-receptor insulin resistance in NIDDM, and it may be a useful tool for studying post-receptor binding events."( Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes.
Greenwood, RH; Hales, CN; Olczak, SA, 1986
)
1.26

Treatment

Diazoxide treatment (3 days of sequential application) reversed the negative effects of OGD and H2O2. Diazoxide pre-treatment induced delayed pre-conditioning and almost entirely attenuated the OGD-induced neuronal death. Diaz oxide pretreatment also significantly inhibited the extravasation of the low molecular weight NaF.

ExcerptReferenceRelevance
"Diazoxide is one such treatment that acts on the pancreatic β-cell in a dose-dependent manner to decrease insulin secretion."( Oral diazoxide versus placebo for severe or recurrent neonatal hypoglycaemia: Neonatal Glucose Care Optimisation (NeoGluCO) study - a randomised controlled trial.
Alsweiler, JM; Ardern, J; Chase, JG; Cutfield, WS; Gamble, GD; Hanning, SM; Harding, JE; Laing, D; McKinlay, CJ; Meyer, MP; Rogers, J; Walsh, E, 2022
)
1.96
"Diazoxide treatment inhibited myocardial autophagy and apoptosis while protecting cardiac tissue from ischemic injury, which is likely to have proceeded through activation of the AKT/mTOR pathway."( Effects of Mitochondrial ATP-Sensitive Potassium Channel in Rats with Acute Myocardial Infarction and Its Association with the AKT/mTOR Pathway.
Chen, QF; Huang, DL; Huang, Z; Nong, J; Wang, F; Wang, W; Yang, F; Yang, J; Zeng, J; Zeng, Q; Zhang, LD, 2023
)
1.63
"Diazoxide is first-line treatment for hyperinsulinaemic hypoglycaemia (HH) but diazoxide-induced pulmonary hypertension (PH) can occur. "( Diazoxide-induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United Kingdom.
Aftab, S; Banerjee, I; Bath, L; Chen, SC; Christov, G; Dastamani, A; Giardini, A; Hunter, L; Pintus, D; Senniappan, S; Shah, P; Shaikh, MG; Swinburne, C; Yau, D, 2019
)
3.4
"Diazoxide treatment was started at median age of 13 days (range 5-35) and discontinued at median age of 42 days (range 14-224)."( Higher C-peptide levels and glucose requirements may identify neonates with transient hyperinsulinism hypoglycemia who will benefit from diazoxide treatment.
Davidov, AS; Elkon-Tamir, E; Eyal, O; Haham, A; Lebenthal, Y; Mandel, D; Oren, A; Shefer, G; Weintrob, N, 2020
)
1.48
"Diazoxide treatment resolved the glycopenic symptoms, the non-hypoglycemic seizures and normalized brain electrical activity allowing complete withdrawal of antiepileptic medication."( Epileptic phenotype in late-onset hyperinsulinemic hypoglycemia successfully treated by diazoxide.
de Bellescize, J; Descamps, J; Nicolino, M; Perge, K; Ruello, C; Saint-Martin, C, 2021
)
1.56
"Diazoxide treatment for 10 days was sufficient to increase pulsatile GH secretion in DIO mice before any significant body weight change."( Suppression of hyperinsulinemia restores growth hormone secretion and metabolism in obese mice.
Chen, C; Chen, Y; Huang, L; Huang, Z; Lu, X; Veldhuis, JD; Zhang, C, 2021
)
1.34
"Diazoxide treatment also modulated the expression levels of OA-related biomarkers."( Diazoxide ameliorates severity of experimental osteoarthritis by activating autophagy via modulation of the osteoarthritis-related biomarkers.
Bian, Y; Chen, K; Cheng, S; Fu, J; Gu, Y; Meng, Z; Peng, L; Shen, B; Wu, Z; Yao, J; Zeng, D; Zhao, Y, 2018
)
2.64
"Diazoxide treatment (30 mg/kg/d, intragastrically) for 28 days accelerated wound closure and stimulated angiogenesis in the diabetic mice."( Diazoxide accelerates wound healing by improving EPC function.
Deng, YP; Jiang, GJ; Li, DJ; Li, ZP; Shen, FM; Xin, RJ; Yang, H, 2016
)
2.6
"Diazoxide treatment attenuated the NMDA-induced hippocampal injury in rats, as demonstrated by decreases in the size of the lesion, neuronal loss and microglial reaction."( Diazoxide enhances excitotoxicity-induced neurogenesis and attenuates neurodegeneration in the rat non-neurogenic hippocampus.
Andrade, C; Batlle, M; Gimeno-Bayón, J; Mahy, N; Martínez-Moreno, M; Ortega, FJ; Rodríguez, MJ, 2016
)
2.6
"Diazoxide treatment remains the mainstay of medical therapy."( Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy.
Erdem, S; Küçükosmanoglu, O; Yildizdas, D; Yilmaz, M; Yüksel, B, 2008
)
1.31
"Diazoxide treatment decreased food intake, weight gain, and body fat in obese rats (P < .01)."( Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats.
Alemzadeh, R; Buchholz, M; Karlstad, MD; Tushaus, K, 2008
)
2.51
"Diazoxide treatment was effective in child 3 but ineffective in child 1 and only partially effective in child 2."( Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations.
Buettger, C; Chen, P; Grimsby, J; Langdon, DR; Matschinsky, FM; Odili, S; Sayed, S; Schiffman, AB; Stanley, CA; Suchi, M; Taub, R, 2009
)
1.07
"Diazoxide pretreatment abolished the caerulein-stimulated amylase secretion, whereas atropine or tetrodotoxin caused a partial inhibition."( Galanin potentiates supramaximal caerulein-stimulated pancreatic amylase secretion via its action on somatostatin secretion.
Barreto, SG; Carati, CJ; Saccone, GT; Schloithe, AC; Toouli, J, 2009
)
1.07
"Diazoxide treatment attenuated cytotoxicity in both cell types and 5-HD treatment-increased cytotoxicity in the sensitive NRK cells in a superoxide-dependant manner."( Variable effects of the mitoK(ATP) channel modulators diazoxide and 5-HD in ATP-depleted renal epithelial cells.
Johnson, CP; Liang, H; Mortensen, J; Nilakantan, V; Taylor, E, 2010
)
1.33
"Diazoxide treatment reduced A1C from 8.6% at baseline to 6.0% at 6 months and 6.5% at 12 months."( Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.
Dørflinger, GH; Grill, V; Hals, I; Kollind, M; Moen, T; Nermoen, I; Radtke, MA; Skeie, S; Svartberg, J; Sørheim, JI, 2010
)
1.44
"Diazoxide treatment significantly decreased the body weight (P<0.05), decreased the blood glucose, increased Bcl-2 expression (P<0.01), decreased Bax expression (P<0.05), and reduced the islet cell apoptosis (P>0.05) of the diabetic rats."( [Effect of K-ATP channel opener diazoxide on islet cell apoptosis and the expressions of apoptosis-related genes].
Wang, HF; Xu, J; Zhang, W, 2010
)
1.37
"Diazoxide treatment might represent a novel therapeutic target for the treatment of ischemic cerebrovascular diseases."( AIF-mediated mitochondrial pathway is critical for the protective effect of diazoxide against SH-SY5Y cell apoptosis.
Feng, J; Luo, Y; Song, LC; Wang, ZQ; Zhang, H; Zhao, DY; Zheng, DM, 2011
)
1.32
"The diazoxide group was pretreated with diazoxide of 100 μmol/L for 24 hrs before hyperxia induction."( [Protective effects of mitochondrial ATP-sensitive potassium channel on A549 cell apoptosis induced by hyperoxia].
Chen, F; Dong, WB; Lei, XP; Li, QP; Zhai, XS; Zou, D; Zou, XY, 2011
)
0.85
"Diazoxide treatment for presumptive insulinoma was started at a dosage of 5 mg/kg (2.3 mg/lb), p.o., every 12 hours. "( Diagnosis and treatment of an insulinoma in a guinea pig (Cavia porcellus).
Hess, LR; Ravich, ML; Reavill, DR, 2013
)
1.83
"Diazoxide-treated animals were dosed (5 mg/kg) 15 minutes before cross-clamp."( Pharmacological preconditioning ameliorates neurological injury in a model of spinal cord ischemia.
Baumgartner, WA; Bethea, BT; Blue, ME; Caparrelli, DJ; Cattaneo, SM; Eberhart, C; Gott, VL; Johnston, MV; Marbán, E; Shake, JG, 2002
)
1.04
"Diazoxide treatment (3 days of sequential application) dramatically reversed the negative effects of OGD and H2O2, resulting in complete blockade of astrocyte cell death."( Diazoxide pretreatment induces delayed preconditioning in astrocytes against oxygen glucose deprivation and hydrogen peroxide-induced toxicity.
Busija, D; Horiguchi, T; Kis, B; Rajapakse, N; Snipes, J, 2003
)
2.48
"Diazoxide pre-treatment induced delayed pre-conditioning and almost entirely attenuated the OGD-induced neuronal death."( Diazoxide induces delayed pre-conditioning in cultured rat cortical neurons.
Busija, DW; Horiguchi, T; Kis, B; Nagy, K; Rajapakse, NC; Snipes, JA, 2003
)
2.48
"Diazoxide pretreatment increases recovery of function and [Ca2+]i following reperfusion. "( Diazoxide causes early activation of cardiac sarcolemmal KATP channels during metabolic inhibition by an indirect mechanism.
Davies, NW; Rodrigo, GC; Standen, NB, 2004
)
3.21
"Diazoxide treatment remains the mainstay of medical therapy."( A case of severe diazoxide toxicity.
Camporesi, A; Mandelli, A; Salvo, I; Silvani, P; Wolfler, A, 2004
)
1.38
"Diazoxide pretreatment also significantly inhibited the extravasation of the low molecular weight NaF."( Diazoxide preconditioning attenuates global cerebral ischemia-induced blood-brain barrier permeability.
Bari, F; Busija, DW; Kis, B; Lenzsér, G, 2005
)
2.49
"Diazoxide pretreatment limited neurologic injury versus HCA alone, reflected in a preserved NAA:Cho ratio (1.21 +/- 0.27 versus 1.01 +/- 0.29; p = 0.05)."( Noninvasive assessment of brain injury in a canine model of hypothermic circulatory arrest using magnetic resonance spectroscopy.
Barker, PB; Barreiro, CJ; Baumgartner, WA; Blue, ME; Degaonkar, M; Fitton, TP; Gott, VL; Johnston, MV; Kratz, L; Lange, MS; Troncoso, JC; Williams, JA, 2006
)
1.06
"In diazoxide- treated hearts, diazoxide (50 micromol/l) was applied 15 min before II."( Changes in rat myocardium associated with modulation of ischemic tolerance by diazoxide.
Andelová, E; Barancík, M; Ravingerová, T; Simoncíková, P; Tribulová, N, 2007
)
1.08
"Diazoxide treatment resulted in a significant suppression of glucose-stimulated early (insulin area 0-30 min) (P less than 0.05), late (insulin area 30-120 min) (P less than 0.01) and total insulin response (insulin area 0-120 min) (P less than 0.01) as well as a mild deterioration of glucose tolerance."( Effect of pharmacological suppression of insulin secretion on tissue sensitivity to insulin in subjects with moderate obesity.
Kohnert, KD; Ratzmann, KP; Ruhnke, R, 1983
)
0.99
"Diazoxide treatment could be stopped at the age of 1 month."( Transient lactic acidosis and hyperalaninaemia associated with neonatal hyperinsulinaemic hypoglycaemia: the effects of dichloroacetate (DCA).
Aynsley-Green, A; Jenkins, PA; Soltész, G; Weindling, AM, 1983
)
0.99
"Diazoxide treatment during the first stimulation profoundly inhibited secretion and, as an aftereffect, completely prevented restimulation-assessed desensitization."( B-cell insensitivity in vitro: reversal by diazoxide entails more than one event in stimulus-secretion coupling.
Björklund, A; Grill, V, 1993
)
1.27
"Diazoxide treatment increased estradiol levels in controls, but not in obese men."( Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men.
Biscotti, M; Boschi, S; Casimirri, F; Chierici, R; De Iasio, R; Flamia, R; Mesini, P; Pasquali, R; Vicennati, V, 1995
)
1.01
"The diazoxide treatment was maintained and propranolol was introduced, which prevented further episodes of hypoglycemia."( Relapse of medically treated insulinoma following the development of thyrotoxicosis: an assessment of potential mechanisms.
Alberti, KG; Kendall-Taylor, P; Trajano, LR; Walker, M, 1994
)
0.77
"Diazoxide-treated obese and lean animals showed significantly lower postabsorptive plasma insulin concentrations (P < 0.005) than their respective obese and lean PF and C subgroups."( Modification of insulin resistance by diazoxide in obese Zucker rats.
Alemzadeh, R; Maturo, J; Slonim, AE; Zdanowicz, MM, 1993
)
1.28
"Diazoxide treatment maintained normoglycemia without causing any side effects, including hypertrichosis."( Long-term diazoxide treatment in persistent hyperinsulinemic hypoglycemia of infancy: a patient report.
Bas, F; Bundak, R; Darendeliler, F; Günöz, H; Saka, N,
)
1.26
"Diazoxide treatment remains the mainstay of medical therapy in long-term management."( Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria.
Brunelle, F; Czernichow, P; Nihoul-Fekete, C; Ogier de Baulny, H; Poggi-Travert, F; Rahier, J; Saudubray, JM; Touati, G, 1998
)
1.25
"Diazoxide treatment increased by 5.5-fold the insulin response to 10 mmol/L arginine, by 4.1-fold the graft insulin content, and by 2.3-fold the preproinsulin mRNA versus nontreated diabetic controls."( Treatment with diazoxide causes prolonged improvement of beta-cell function in rat islets transplanted to a diabetic environment.
Grill, V; Hiramatsu, S; Höög, A; Möller, C, 2000
)
1.38
"Diazoxide treatment conferred protection against LSI/R (13.9+/-0.9% vs."( Mitochondrial K(ATP) channel opening protects a human atrial-derived cell line by a mechanism involving free radical generation.
Carroll, R; Gant, VA; Yellon, DM, 2001
)
1.03
"Diazoxide pretreatment significantly increased nuclear translocation of p65 which was blocked by protein kinase C (PKC) or nitric oxide synthase (NOS) inhibition."( Mitochondrial K(ATP) channel as an end effector of cardioprotection during late preconditioning: triggering role of nitric oxide.
Ashraf, M; Ayub, A; Kudo, M; Wang, Y; Xu, M, 2001
)
1.03
"Diazoxide pretreatment significantly improved the recovery of LV function and coronary flow compared to control (LVDP: 49 +/- 5* vs."( Diazoxide protects the rabbit heart following cardioplegic ischemia.
Feng, J; Li, H; Rosenkranz, ER, 2002
)
2.48
"Diazoxide treatment resulted in suppressed insulin release during a 100-g oral glucose tolerance test (insulin area under the curve, 262 +/- 55 nmol/min.L on day 0 vs."( A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
Blackard, WG; Clore, JN; Matt, DW; Nestler, JE; Plymate, SR; Powers, LP; Rittmaster, RS; Steingold, KA, 1991
)
1
"Treatment with diazoxide partially normalizes obesity in children and adults with PWS and in a PWS mouse model, demonstrating that the biological pathways impacted by diazoxide may be rational pharmacological targets in PWS and other disorders diseases associated with obesity."( Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome.
Bischof, JM; Wevrick, R, 2018
)
1.25
"Treatment with diazoxide in wild-type mice decreased IOP by 21.5 ± 3.2% with an absolute IOP reduction of 3.9 ± 0.6 mm Hg (P = 0.002)."( ATP-sensitive potassium (K(ATP)) channel openers diazoxide and nicorandil lower intraocular pressure in vivo.
Chowdhury, UR; Fautsch, MP; Holman, BH, 2013
)
0.98
"Pretreatment with diazoxide attenuates doxorubicin-induced cardiac dysfunction in the rat, measured by physiological indices and TnT and H2O2 in effluate from isolated hearts. "( Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat.
Fossan, KO; Hole, LD; Larsen, TH; Limé, F; Schjøtt, J, 2014
)
2.18
"Treatment with diazoxide resulted in disappearance of hypoglycemic episodes."( Reversal of impaired counterregulatory cortisol response following diazoxide treatment in a patient with non insulinoma pancreatogenous hypoglycemia syndrome: Case report and overview of pathogenetic mechanisms.
Fountoulakis, S; Karydas, G; Malliopoulos, D; Papanastasiou, L; Pappa, T; Piaditis, G,
)
0.71
"Treatment with diazoxide (a mitoKATP opener, 5 mg·kg·d) normalized the levels of protein thiols and reduced glutathione, rescued superoxide dismutase activity, and significantly prevented cardiac hypertrophy."( Mitochondrial ATP-sensitive potassium channel opening inhibits isoproterenol-induced cardiac hypertrophy by preventing oxidative damage.
de Figueiredo Júnior, IL; Fernandes Facundo, Hd; Gomes Marques de Sousa, TA; Kowaltowski, AJ; Lemos Caldas, FR; Martins, PR; Rocha Leite, IM; Tavarez Filgueiras, AB, 2015
)
0.76
"Pretreatment with diazoxide (0.01 approximately 1 microM) also decreased the release of reactive oxygen species and the increase in oxidative damage markers (protein carbonyl and malondialdehyde) induced by H2O2 in osteoblastic MC3T3-E1 cells."( Diazoxide protects against hydrogen peroxide-induced toxicity in the osteoblastic MC3T3-E1 cells.
Choi, EM; Kim, GH; Lee, YS, 2009
)
2.12
"Pretreatment with diazoxide, a mitochondrial ATP-sensitive potassium channel (mito KATP) opener, was found to protect the rat heart against ischaemia-reperfusion (I/R) injury by mimicking ischaemic preconditioning (IPC). "( Myocardial ischaemic and diazoxide preconditioning both increase PGC-1alpha and reduce mitochondrial damage.
Han, HG; Han, JS; Li, XM; Wang, HS; Wang, ZW; Yan, DM; Zhu, HY, 2010
)
1
"Pretreatment with diazoxide significantly reduced infarct volume and brain edema formation after ASDH."( The neuroprotective effect of diazoxide is mediated by mitochondrial ATP-dependent potassium channels in a rat model of acute subdural hematoma.
Nakagawa, I; Nakase, H; Nishimura, F; Park, YS; Tamura, K; Wajima, D, 2013
)
1
"Pretreatment with diazoxide, K(ATP) channel opener, increases tissue tolerance against ischemia reperfusion (IR) injury. "( Skeletal muscle post-conditioning by diazoxide, anti-oxidative and anti-apoptotic mechanisms.
Ajami, M; Ebrahimi, SA; Habibey, R; Moghtadaei, M; Pazoki-Toroudi, H; Soleimani, M, 2012
)
0.99
"Pretreatment with diazoxide protected both Sur1KO and wild-type neurons, while 5-hydroxydecanoate augmented neurodegeneration in both strains of animals when administered before a 20-minute bout of ischemia."( Ischemic preconditioning in the hippocampus of a knockout mouse lacking SUR1-based K(ATP) channels.
Aguilar-Bryan, L; Barrios, R; Bryan, J; Goodman, JC; Muñoz, A; Nakazaki, M; Onetti, CG, 2003
)
0.64
"Treatment with diazoxide did not incur any increase in bedtime insulin."( Nine weeks of bedtime diazoxide is well tolerated and improves beta-cell function in subjects with Type 2 diabetes.
Grill, V; Kollind, M; Qvigstad, E, 2004
)
0.98
"Pretreatment with diazoxide (100 microM, 5 min) increased the proportion of cells that recovered contractile function after MI and reperfusion from 16.8 +/- 2.4% to 65.0 +/- 2.2% (p<0.001) and the proportion of cells in which [Ca2+]i recovered to <250 nM. "( Diazoxide causes early activation of cardiac sarcolemmal KATP channels during metabolic inhibition by an indirect mechanism.
Davies, NW; Rodrigo, GC; Standen, NB, 2004
)
2.1
"The treatment with diazoxide or infection of ORP150 antisense adenovirus suppressed ORP150 expression, and glucose-stimulated insulin secretion was effectively prevented."( 150-kD oxygen-regulated protein is an essential factor for insulin release.
Kobayashi, T; Ohta, Y, 2005
)
0.65
"Treatment with diazoxide and chlorthiazide is highly effective, appears to be safe, and does not need to be continued lifelong."( Hyperinsulinism in tyrosinaemia type I.
Baumann, U; Green, A; Kelly, DA; McKiernan, PJ; Preece, MA, 2005
)
0.67
"(1) Treatment of diazoxide improved the recovery of left ventricular developed pressure and decreased the leakage of myocardial enzymes, lactate dehydrogenase (LDH) and creatine kinase (CK), at the 2nd and 4th minute of reperfusion of rat heart after hypothermic preservation for 3 h. "( [Protective effect of mitochondrial ATP-sensitive potassium channel opener on rat heart during hypothermic preservation].
Chen, YY; Guo, W; Hu, ZB; Shen, YL; Xia, Q; Yan, ZK, 2005
)
0.67
"Pretreatment with diazoxide significantly reduced the infarct volume from 6.2 +/- 0.7 mm3 to 3.8 +/- 0.4 mm3, whereas regional cerebral blood flow in the vicinity of the two veins was comparable in both groups 70 minutes after two-vein occlusion. "( MitoKATP-channel opener protects against neuronal death in rat venous ischemia.
Alessandri, B; Heimann, A; Kempski, O; Nakagawa, I, 2005
)
0.66
"Pretreatment with diazoxide (20 to 100 micromol/L) prevented H2O2-induced apoptosis and DeltaPsim loss at 2 but not 18 h after exposure, while the latter was prevented by cotreatment with diazoxide."( Diazoxide-induced cardioprotection via DeltaPsim loss depending on timing of application.
Anan, F; Ichinose, M; Nakagawa, M; Saikawa, T; Shinohara, T; Takahashi, N; Taniguti, Y; Yonemochi, H, 2006
)
2.1
"Pretreatment with diazoxide resulted in a significant intracellular Ca and Mg loss in each experimental situation."( Total cellular calcium and magnesium content of cultured human peripheral blood mononuclear cells following exposure to antidiabetic drugs.
Almoznino-Sarafian, D; Alon, I; Berman, S; Cohen, N; Efrati, S; Gorelik, O; Shteinshnaider, M; Weissgarten, J, 2006
)
0.66
"Pretreatment with diazoxide, mitochondrial K(ATP) channel opener, was found to protect the rat heart against ischemia/reperfusion injury. "( Changes in rat myocardium associated with modulation of ischemic tolerance by diazoxide.
Andelová, E; Barancík, M; Ravingerová, T; Simoncíková, P; Tribulová, N, 2007
)
0.9
"Pretreatment with diazoxide (10 mg.kg-1, i.v.) significantly attenuated the accumulation of lactate due to global ischemia."( Effects of diazoxide on norepinephrine-induced vasocontraction and ischemic myocardium in rats.
Ichihara, K; Nakai, T, 1994
)
1
"When treatment with diazoxide and somatostatin for persistent hyperinsulinaemic hypoglycaemia of infancy failed, subtotal pancreatectomy was performed on a neonate on day 41. "( Histochemical, clinical, and in vitro beta cell responses in a neonate with persistent hyperinsulinaemic hypoglycaemia of infancy.
Hjelm, NM; Liew, CT; Panesar, NS; Poon, CW; Wong, GW, 1998
)
0.62
"Pretreatment with diazoxide (100 microM), a selective mK(ATP) channel opener, for 5 min followed by 10 min washout before the 30-min ischemia and 2-h reperfusion significantly reduced infarct size (9 +/- 3 vs."( Dual roles of mitochondrial K(ATP) channels in diazoxide-mediated protection in isolated rabbit hearts.
Cone, J; Liu, Y; Wang, S, 2001
)
0.89
"Pretreatment with diazoxide (100 microM) with a 10-min washout period reduced %IS/LV to 7.8+/-2.4 and this protection was abolished by co-infusion of 5-HD (50 microM)."( Critical timing of mitochondrial K(ATP) channel opening for enhancement of myocardial tolerance against infarction.
Genda, S; Kuno, A; Matsumoto, T; Miki, T; Miura, T; Nozawa, Y; Shimamoto, K; Tanno, M; Tsuchida, A, 2001
)
0.63
"Pretreatment with diazoxide resulted in significant improvement in both clinical neurologic scores and histopathology in our model of HCA. "( Pharmacologically induced preconditioning with diazoxide: a novel approach to brain protection.
Baumgartner, WA; Gott, VL; Johnston, MV; Marban, E; Peck, EA; Redmond, JM; Shake, JG; Troncoso, JC, 2001
)
0.9
"Treatment with diazoxide and chlorothiazide was effective."( The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy.
Barbetti, F; Brusgaard, K; Buettger, C; Christesen, HB; Cuesta-Munoz, A; Hansen, T; Jacobsen, BB; Magnuson, MA; Massa, O; Matschinsky, FM; Odili, S; Shiota, C, 2002
)
0.65
"Treatment with diazoxide is rational and effective and may be lifesaving."( Clinical spectrum of sulfonylurea overdose and experience with diazoxide therapy.
Meatherall, RC; Palatnick, W; Tenenbein, M, 1991
)
0.86
"Treatment with diazoxide shortly before the meal, to inhibit insulin release, almost completely inhibited the thermic responses to carbohydrate and methyl cellulose in all groups, but did not alter the effects of fat or water."( Involvement of insulin in the acute thermogenic responses to food and nonmetabolizable substances.
Rothwell, NJ; Stock, MJ; Warwick, BP, 1985
)
0.61
"Treatment with diazoxide could be continued in four of these."( Development of extrapyramidal symptoms in hypertensive patients treated with diazoxide.
Neary, D; Pohl, JE; Thurston, H, 1973
)
0.82

Toxicity

Diazoxide (DZX) is the drug of choice for treating hyperinsulinaemic hypoglycaemia. Tolerance of diazoxide is usually excellent, but several adverse effects of this drug have been described.

ExcerptReferenceRelevance
" No serious adverse circulatory, fluid and electrolyte, metabolic or hematologic effects were observed."( Safety of intravenous diazoxide in children with severe hypertension.
Kohaut, EC; Lewy, JE; Lieberman, E; McCrory, WW; Travis, LB, 1979
)
0.57
" Tolerance of diazoxide is usually excellent, but several adverse effects of this drug have been described."( A case of severe diazoxide toxicity.
Camporesi, A; Mandelli, A; Salvo, I; Silvani, P; Wolfler, A, 2004
)
1.02
" Conversely, decreasing human IAPP release with diazoxide or somatostatin limited amyloid formation and its toxic effects."( Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.
Aston-Mourney, K; Hull, RL; Kahn, SE; Subramanian, SL; Udayasankar, J; Zraika, S, 2011
)
0.62
"IAPP release is necessary for islet amyloid formation and its toxic effects."( Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets.
Aston-Mourney, K; Hull, RL; Kahn, SE; Subramanian, SL; Udayasankar, J; Zraika, S, 2011
)
0.37
" I-PostC may induce the activation of RISK and SAFE pathways and may favor nitric oxide production with S-Nitrosylation of proteins and redox signaling."( Diazoxide postconditioning induces mitochondrial protein S-nitrosylation and a redox-sensitive mitochondrial phosphorylation/translocation of RISK elements: no role for SAFE.
Angotti, C; Camporeale, A; Pagliaro, P; Penna, C; Perrelli, MG; Poli, V; Tullio, F, 2013
)
1.83
" Diazoxide is an effective and usually safe medication to treat this type and other types of neonatal HI."( Liver injury may increase the risk of diazoxide toxicity: a case report.
Garibaldi, L; Mahmood, B; Sperling, M; Tas, E, 2015
)
1.6
" Although patients with hyperinsulinemic hypoglycemia worldwide have been treated with diazoxide for more than 30 years, there are no recent reports about the adverse effects of this drug in Asian patients, including Japanese patients."( Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia.
Inoue, Y; Komatsu, Y; Miyoshi, H; Nakamura, A; Tajima, K; Takano, T; Takihata, M; Terauchi, Y; Tsuchiya, H; Yahagi, S; Yamakawa, T; Yoshida, M, 2016
)
0.95
"Diazoxide, a well-known mitochondrial KATP channel opener with neuroprotective effects, has been proposed for the effective and safe treatment of neuroinflammation."( Diazoxide enhances excitotoxicity-induced neurogenesis and attenuates neurodegeneration in the rat non-neurogenic hippocampus.
Andrade, C; Batlle, M; Gimeno-Bayón, J; Mahy, N; Martínez-Moreno, M; Ortega, FJ; Rodríguez, MJ, 2016
)
3.32
"02) were significantly lower in the diazoxide group, with no adverse effects attributed to the drug."( Randomised controlled trial of diazoxide for small for gestational age neonates with hyperinsulinaemic hypoglycaemia provided early hypoglycaemic control without adverse effects.
Attri, SV; Balachandran, B; Mukhopadhyay, K; Sachdeva, N; Walia, R, 2018
)
1.04
"Using oral diazoxide for SGA neonates with HH provided early hypoglycaemic control with no apparent adverse effects."( Randomised controlled trial of diazoxide for small for gestational age neonates with hyperinsulinaemic hypoglycaemia provided early hypoglycaemic control without adverse effects.
Attri, SV; Balachandran, B; Mukhopadhyay, K; Sachdeva, N; Walia, R, 2018
)
1.16
"Diazoxide is used to treat infants with persistent hypoglycemia, but the prevalence of its use and adverse effects are not well described."( Prevalence and safety of diazoxide in the neonatal intensive care unit.
Benjamin, DK; Benjamin, R; Clark, RH; Cotten, CM; Dudash, K; Escobar, C; Freel, C; Gray, KD; Greenberg, RG; Harrison, T; McMillan, C; Puia-Dumitrescu, M, 2018
)
2.23
" Food and Drug Administration-approved drug to treat hyperinsulinemic hypoglycemia, has been associated with several adverse events, which has raised concerns about the safety of this drug."( Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
Avitabile, CM; De León, DD; Givler, S; Herrera, A; Lord, K; Mitteer, L; Vajravelu, ME, 2018
)
0.7
"To determine prevalence of and clinical factors associated with adverse events in infants and children treated with diazoxide."( Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
Avitabile, CM; De León, DD; Givler, S; Herrera, A; Lord, K; Mitteer, L; Vajravelu, ME, 2018
)
0.91
" Other adverse events included neutropenia (15."( Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
Avitabile, CM; De León, DD; Givler, S; Herrera, A; Lord, K; Mitteer, L; Vajravelu, ME, 2018
)
0.7
"In this large cohort, PH occurred in infants with underlying risk factors, but no identifiable risk profile emerged for other adverse events."( Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
Avitabile, CM; De León, DD; Givler, S; Herrera, A; Lord, K; Mitteer, L; Vajravelu, ME, 2018
)
0.7
"We performed a retrospective analysis of 194 patients with hyperinsulinism in our clinic and looked for those who had experienced serious adverse events (SAE) including pulmonary hypertension and neutropenia."( Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism.
Hamby, T; Nedrelow, J; Reynolds, C; Thornton, P; Truong, L, 2019
)
0.77
" The most common adverse events were peripheral edema and transient increases in glucose."( A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome.
Cowen, NM; Gold, JA; Kimonis, V; Surampalli, A; Wencel, M, 2019
)
0.77
" Other adverse events included pulmonary hypertension (2%) and thrombocytopenia (2%)."( Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis.
Chen, X; Feng, L; Qin, Y; Yang, L; Yao, H, 2021
)
0.93
"Diazoxide (DZX) is the drug of choice for treating hyperinsulinaemic hypoglycaemia (HH), and it has potentially serious adverse effects."( Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia.
Chandran, S; Mei Chien, C; R, PR; Rajadurai, VS; Saffari, SE; Yap, F, 2022
)
2.45
"Short-term outcomes; adverse drug events and fasting studies to determine 'safe to go home' and 'resolution' of HH."( Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia.
Chandran, S; Mei Chien, C; R, PR; Rajadurai, VS; Saffari, SE; Yap, F, 2022
)
1
" Although the safety profile was excellent, minimal adverse events were still observed with DZX, even at low doses."( Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia.
Chandran, S; Mei Chien, C; R, PR; Rajadurai, VS; Saffari, SE; Yap, F, 2022
)
1
"Doxorubicin-induced cardiotoxicity (DIC) is a common side effect of doxorubicin chemotherapy, and a major mechanism of DIC is inflammation."( Nicorandil Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats, as Evaluated by 7 T Cardiovascular Magnetic Resonance Imaging.
Gao, F; He, B; Huang, R; Ma, L; Wan, Y; Wang, C; Wang, L; Wang, S; Zhang, M; Zhu, D, 2023
)
0.91

Pharmacokinetics

We have proposed for the first time a population pharmacokinetic model for diazoxide in children with HI. Measured serum d Diazoxide concentrations were used for population Pharmacokinetic analysis.

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Measured serum diazoxide concentrations were used for population pharmacokinetic analysis."( Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia.
Hasegawa, T; Kizu, R; Kosaki, K; Nishimura, K; Sato, R; Tanaka, T; Tanigawara, Y, 2017
)
1.09
"We have proposed for the first time a population pharmacokinetic model for diazoxide in children with HI."( Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia.
Hasegawa, T; Kizu, R; Kosaki, K; Nishimura, K; Sato, R; Tanaka, T; Tanigawara, Y, 2017
)
0.97

Compound-Compound Interactions

The effects of preconditioning with diazoxide (DZ), a mitochondrial ATP-sensitive potassium channel opener, combined with subsequent hypothermia on anoxia-re-oxygenation injury were studied. The influence on the therapeutic efficacy of the combination with d Diazoxide, causing a mild, reversible diabetes, and with insulin was investigated.

ExcerptReferenceRelevance
" In addition, the influence on the therapeutic efficacy of the combination with diazoxide, causing a mild, reversible diabetes, and with insulin was investigated."( Antineoplastic efficacy of melphalan and N-(2-chloroethyl)-N-nitrosocarbamoyl-omega-lysine, in combination with diazoxide or insulin in autochthonous mammary carcinoma of the Sprague-Dawley rat.
Berger, MR; Fink, M; Klenner, T; Schmähl, D; Zelezny, O, 1990
)
0.72
" Therefore, pharmacological preconditioning with diazoxide in combination with adenosine and a nitric oxide donor (triple-combination pharmacological preconditioning) may enhance cardioprotection."( Integrated pharmacological preconditioning in combination with adenosine, a mitochondrial KATP channel opener and a nitric oxide donor.
Imamura, H; Kido, M; Nakao, S; Ninomiya, H; Okada, T; Otani, H; Shingu, K; Uchiyama, T; Uchiyama, Y, 2003
)
0.57
"To observe the alleviative effects of preconditioning with diazoxide (DZ), a mitochondrial ATP-sensitive potassium channel opener, combined with subsequent hypothermia on anoxia-re-oxygenation injury."( [Diazoxide preconditioning combined with subsequent hypothermia alleviates anoxia-re-oxygenation injury: experiment with rat hippocampal neurons].
Gai, XD; Li, LH; Liu, RG; Wang, WJ, 2005
)
1.48

Bioavailability

ExcerptReferenceRelevance
" Therefore, one possible mechanism accounting for the more rapid and short-lived hypoglycemic action of A-4166 in vivo, as compared with tolbutamide, may involve the reported differences in the bioavailability of A-4166."( Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine.
Kikuchi, M; Niki, I; Oka, Y; Sakurada, M; Tsukuda, K, 1998
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The therapeutic success of peptidic GLP-1 receptor agonists for treatment of type 2 diabetes mellitus (T2DM) motivated our search for orally bioavailable small molecules that can activate the GLP-1 receptor (GLP-1R) as a well-validated target for T2DM."( Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
Breitschopf, K; Defossa, E; Kurz, M; Lebreton, S; Li, Z; Lohmann, M; Löhn, M; Matter, H; Méndez, M; Mors, H; Podeschwa, M; Rackelmann, N; Riedel, J; Safar, P; Schäfer, M; Thorpe, DS; Weitz, D, 2020
)
0.56

Dosage Studied

Diazoxide was found to be of value for inhibiting uterine activity in early labor, without interfering with the fetal well-being.

ExcerptRelevanceReference
" Thus, a slow intravenous infusion of diazoxide to the mother in a low dosage appears to be of value for inhibiting the uterine activity in early labor, without interfering with the fetal well-being."( Prolonged infusion of diazoxide in the management of premature labor in the baboon.
Caritis, SN; James, LS; Morishima, HO; Yeh, MN, 1976
)
0.84
"The effect of diazoxide, verapamil and compound D600 on calcium and isoproterenol dose-response relationships was investigated in isolated rabbit atrial preparations."( Effect of diazoxide, verapamil and compound D600 on isoproterenol and calcium-mediated dose-response relationships in isolated rabbit atrium.
Bristow, MR; Green, RD, 1977
)
1.02
" Although usually effective, this standard dosage may decrease the blood pressure too much, inducing hypotensive problems."( Individual titration of diazoxide dosage in the treatment of severe hypertension.
Kaplan, NM; Ram, CV, 1979
)
0.57
" Dose-response curves to Ba2+ in SHR strips were displaced to the right as compared to NW rats."( Evidence for a visceral smooth muscle abnormality in Okamoto spontaneous hypertension.
Altman, J; Da Ponte, F; Worcel, M, 1977
)
0.26
"001), linear log dose-response relation was obtained which showed that a 3 mg/kg dose of diazoxide lowered diastolic BP by an average of 30 mm Hg."( Dose-response relation of diazoxide in children with hypertension.
Boerth, RC; Long, WR, 1977
)
0.78
" The upper limit of dosage was 15 mg/kg."( [Leucine sensitive hypoglycemia. Follow-up studies under treatment with diazoxide (author's transl)].
Lücking, T, 1976
)
0.49
" It is concluded that a gradual fall in BP can be obtained after fractionated dosage of diazoxide (i."( Severe hypertension with cerebral symptoms treated with furosemide, fractionated diazoxide or dihydralazine. Danish Multicenter Study.
Hilden, T; Krogsgaard, AR; McNair, A; Nielsen, PE, 1986
)
0.72
" The symptoms are usually controllable either by dosage adjustment or by the use of diazepam or procyclidine."( Development of extrapyramidal symptoms in hypertensive patients treated with diazoxide.
Neary, D; Pohl, JE; Thurston, H, 1973
)
0.48
" Only minimal adjustments of insulin dosage were required."( Successful use of oral diazoxide in the treatment of severe toxaemia of pregnancy.
Davis, D; Morgan, MY; Pohl, JE; Thurston, H, 1972
)
0.56
" Vasodilators are active within a fairly wide dosage range, making individualized dosages requisite."( [Antihypertensive vasodilators].
Plouin, PF, 1983
)
0.27
" Dose-response relationships for endralazine, hydralazine and diazoxide, administered intravenously, were compared, and the interactions of endralazine with the ganglionic blocking agent, pentolinium, or with adrenaline, noradrenaline and angiotensin II were examined."( Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine.
Oates, HF; Stoker, LM,
)
0.37
" LFLX (100 microM) shifted the dose-response curve of glucose-induced insulin release to the left without altering the maximal response."( Increase in insulin release from rat pancreatic islets by quinolone antibiotics.
Iguchi, A; Maeda, N; Miura, H; Niki, I; Nonogaki, K; Ozawa, K; Tamagawa, T; Uemura, K; Watanabe, G, 1996
)
0.29
" By applying the patch-clamp technique, dose-response curves for ATP and the sulfonylurea tolbutamide were obtained in inside-out patches."( RIN14B: a pancreatic delta-cell line that maintains functional ATP-dependent K+ channels and capability to secrete insulin under conditions where it no longer secretes somatostatin.
Berggren, PO; Bränström, R; Höög, A; Larsson, O; Wahl, MA, 1997
)
0.3
" The treatment of fasted animals with nicotinic acid, an inhibitor of lipolysis, produces a decrease in the levels of free fatty acids (FFAs) and a decrease in electrical activity, thereby restoring the dose-response curve for glucose in fasted animals to values close to those found in fed animals."( Increased levels of free fatty acids in fasted mice stimulate in vivo beta-cell electrical activity.
Fernandez, J; Valdeolmillos, M, 1998
)
0.3
" Diazoxide (2 microg/mouse) shifted morphine's dose-response curve 47-fold, while levcromakalim (0."( ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides.
Lohmann, AB; Welch, SP, 1999
)
1.21
" Co-culture with diazoxide left-shifted the insulin dose-response to a cAMP analogue 5,6-dichloro-1-beta-d> -ribofuranosyl-benzimidazole-3',5'-cyclic monophosphorothioate."( Relief from glucose-induced over-stimulation sensitizes the adenylate cyclase-cAMP system of rat pancreatic islets.
Björklund, A; Grill, VE, 2000
)
0.65
" Diazoxide-treated animals were dosed (5 mg/kg) 15 minutes before cross-clamp."( Pharmacological preconditioning ameliorates neurological injury in a model of spinal cord ischemia.
Baumgartner, WA; Bethea, BT; Blue, ME; Caparrelli, DJ; Cattaneo, SM; Eberhart, C; Gott, VL; Johnston, MV; Marbán, E; Shake, JG, 2002
)
1.22
"In order to study the cardioprotective effects of diazoxide on the myocardial ischemia/reperfusion injury of rats and mechanisms, the healthy SD rats were randomly divided into 2 groups: the rats in the experimental group were injected with diazoxide for preconditioning with the dosage of 12."( Cardioprotective effects of diazoxide on myocardial ischemia/reperfusion injury in rats.
Hu, Z; Yang, Y; Zhang, K; Zhao, J, 2006
)
0.88
" In a double-blind study, we tested whether lower, intermittent dosing of diazoxide had beneficial effects on insulin production, metabolic control, and autoimmunity markers in the absence of side effects."( Six months of diazoxide treatment at bedtime in newly diagnosed subjects with type 1 diabetes does not influence parameters of {beta}-cell function and autoimmunity but improves glycemic control.
Dørflinger, GH; Grill, V; Hals, I; Kollind, M; Moen, T; Nermoen, I; Radtke, MA; Skeie, S; Svartberg, J; Sørheim, JI, 2010
)
0.95
" We investigated ABCC8 and KCNJ11 gene dosage in 29 probands from a cohort of 125 with diazoxide-unresponsive HH where sequencing did not provide a genetic diagnosis."( Partial ABCC8 gene deletion mutations causing diazoxide-unresponsive hyperinsulinaemic hypoglycaemia.
Banerjee, I; Damhuis, A; Ellard, S; Flanagan, S; Hussain, K; Jefferies, C; Kapoor, R; Rokicki, D, 2012
)
0.86
" Prior to initial examination, the animal was treated with corn syrup whenever it appeared lethargic, plus an unknown dosage of sulfadimethoxazole."( Diagnosis and treatment of an insulinoma in a guinea pig (Cavia porcellus).
Hess, LR; Ravich, ML; Reavill, DR, 2013
)
0.39
"Diazoxide treatment for presumptive insulinoma was started at a dosage of 5 mg/kg (2."( Diagnosis and treatment of an insulinoma in a guinea pig (Cavia porcellus).
Hess, LR; Ravich, ML; Reavill, DR, 2013
)
1.83
" We aimed to assemble more objective information on medical treatment in CHI with regard to type and duration, dosage as well as side effects."( Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers.
Kummer, S; Lerch, C; Marquard, J; Mayatepek, E; Meissner, T; Salgin, B; Welters, A, 2015
)
0.42
" CHI severity was assessed by glucose infusion rate (GIR), medication dosage and tendency to resolution."( Conservatively treated Congenital Hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time.
Banerjee, I; Bowden, L; Cosgrove, KE; Craigie, R; Dunne, MJ; Ellard, S; Flanagan, SE; Hall, C; Mohamed, Z; Murphy, N; Nicholson, J; Padidela, R; Randell, T; Rigby, L; Salomon-Estebanez, M; Skae, M, 2016
)
0.43
" Steady-state concentrations of diazoxide were similar following twice- and 3 times-daily dosing when the total daily doses were comparable."( Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia.
Hasegawa, T; Kizu, R; Kosaki, K; Nishimura, K; Sato, R; Tanaka, T; Tanigawara, Y, 2017
)
1.02
"Western blot analysis demonstrated that optimal βcR up-regulation occurred at 36 hours after DZ administration, and the optimal DZ dosage for βcR induction was 20 mg/kg."( Optimized induction of beta common receptor enhances the neuroprotective function of erythropoietin in spinal cord ischemic injury.
Aftab, M; Cleveland, JC; Eldeiry, M; Fullerton, DA; Mares, J; Meng, X; Reece, TB; Ryan, TJ; Weyant, MJ; Yamanaka, K, 2018
)
0.48
" Third, DZ significantly inhibited ROS surge during reperfusion with a dose-response manner."( Diazoxide Preconditioning of Nonhuman Primate Pancreas Improves Islet Isolation Outcomes by Mitochondrial Protection.
Bochenek, M; He, Y; Marchese, E; McGarrigle, JJ; Mendoza-Elias, JE; Oberholzer, J; Qi, M; Wang, Y; Xing, Y,
)
1.57
" Despite its increasing use, there is little information regarding dosing of diazoxide and/or monitoring for AEs."( Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.
Brar, PC; Cossen, K; De Leon, DD; Heksch, R; Kamboj, MK; Marks, SD; Marshall, BA; Miller, R; Mitchell, D; Page, L; Stanley, T; Thornton, P, 2020
)
1.07
" We summarized the information on AEs reported to date and have provided practical ideas for dosing and monitoring for AEs in infants treated with diazoxide."( Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.
Brar, PC; Cossen, K; De Leon, DD; Heksch, R; Kamboj, MK; Marks, SD; Marshall, BA; Miller, R; Mitchell, D; Page, L; Stanley, T; Thornton, P, 2020
)
1.04
" Moreover, we were able to calculate the effective dosage of lanreotide in CHI patients which fulfilled the clinical demand."( [The use of long-acting somatostatin analogs in congenital hyperinsulinism].
Gubaeva, DN; Melikyan, MA; Novokreshhennyx, EE, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (9)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
sodium channel blockerAn agent that inhibits sodium influx through cell membranes.
vasodilator agentA drug used to cause dilation of the blood vessels.
K-ATP channel agonistA compound which acts as an agonist at the ATP-sensitive K+ channel.
beta-adrenergic agonistAn agent that selectively binds to and activates beta-adrenergic receptors.
cardiotonic drugA drug that has a strengthening effect on the heart or that can increase cardiac output.
bronchodilator agentAn agent that causes an increase in the expansion of a bronchus or bronchial tubes.
sympathomimetic agentA drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
benzothiadiazineHeterocyclic compound of a ring with sulfur and two nitrogen atoms fused to a benzene ring. Members inhibit sodium-potassium-chloride symporters and are used as diuretics.
sulfoneAn organosulfur compound having the structure RS(=O)2R (R =/= H).
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (52)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency17.78280.044717.8581100.0000AID485294
Chain A, Ferritin light chainEquus caballus (horse)Potency0.22395.623417.292931.6228AID485281
ATAD5 protein, partialHomo sapiens (human)Potency1.83490.004110.890331.5287AID493106
GLS proteinHomo sapiens (human)Potency7.07950.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency25.22580.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency14.14880.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency20.48390.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency1.49890.531815.435837.6858AID504845
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.00120.000229.305416,493.5996AID743075
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.81840.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency7.94330.00207.533739.8107AID891
D(1A) dopamine receptorHomo sapiens (human)Potency1.29950.02245.944922.3872AID488982
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency6.30960.010039.53711,122.0200AID1479
importin subunit beta-1 isoform 1Homo sapiens (human)Potency6.51315.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency6.51315.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency6.51315.804816.996225.9290AID540253
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency12.58930.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency2.81840.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency4.05330.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency1.58490.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency1.27290.891312.067628.1838AID1459; AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)422.66670.11007.190310.0000AID1443980; AID1449628; AID1473738
Coagulation factor VIIHomo sapiens (human)IC50 (µMol)740.00000.00020.83363.3000AID267952
Tissue factorHomo sapiens (human)IC50 (µMol)740.00000.00010.734410.0000AID267952
ATP-binding cassette sub-family C member 8Homo sapiens (human)IC50 (µMol)470.50000.00431.07038.2000AID208996; AID208997; AID267952; AID267953
ATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)IC50 (µMol)470.50000.00431.36868.2000AID208996; AID208997; AID267952; AID267953
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 8Homo sapiens (human)EC50 (µMol)23.01670.02191.12578.8000AID267948; AID286541; AID286542; AID42231; AID444907; AID95325
ATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)EC50 (µMol)23.01670.02190.97088.8000AID267948; AID286541; AID286542; AID42231; AID444907; AID95325
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor 1Rattus norvegicus (Norway rat)EC2x (µMol)448.00001.60001.60001.6000AID92192
Glutamate receptor 1Rattus norvegicus (Norway rat)EC5X (µMol)1,000.00009.80009.80009.8000AID92196
Glutamate receptor 2Rattus norvegicus (Norway rat)EC2x (µMol)448.00001.60001.60001.6000AID92192
Glutamate receptor 2Rattus norvegicus (Norway rat)EC5X (µMol)1,000.00009.80009.80009.8000AID92196
Glutamate receptor 3Rattus norvegicus (Norway rat)EC2x (µMol)448.00001.60001.60001.6000AID92192
Glutamate receptor 3Rattus norvegicus (Norway rat)EC5X (µMol)1,000.00009.80009.80009.8000AID92196
Glutamate receptor 4Rattus norvegicus (Norway rat)EC2x (µMol)448.00001.60001.60001.6000AID92192
Glutamate receptor 4Rattus norvegicus (Norway rat)EC5X (µMol)1,000.00009.80009.80009.8000AID92196
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (127)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
insulin receptor signaling pathwayNicotinamide phosphoribosyltransferaseHomo sapiens (human)
adipose tissue developmentNicotinamide phosphoribosyltransferaseHomo sapiens (human)
signal transductionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
cell-cell signalingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of cell population proliferationNicotinamide phosphoribosyltransferaseHomo sapiens (human)
circadian regulation of gene expressionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayNicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINicotinamide phosphoribosyltransferaseHomo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processNicotinamide phosphoribosyltransferaseHomo sapiens (human)
NAD biosynthetic processNicotinamide phosphoribosyltransferaseHomo sapiens (human)
intracellular glucose homeostasisATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion transportATP-binding cassette sub-family C member 8Homo sapiens (human)
female pregnancyATP-binding cassette sub-family C member 8Homo sapiens (human)
memoryATP-binding cassette sub-family C member 8Homo sapiens (human)
visual learningATP-binding cassette sub-family C member 8Homo sapiens (human)
response to pHATP-binding cassette sub-family C member 8Homo sapiens (human)
response to xenobiotic stimulusATP-binding cassette sub-family C member 8Homo sapiens (human)
response to zinc ionATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of low-density lipoprotein particle clearanceATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of angiogenesisATP-binding cassette sub-family C member 8Homo sapiens (human)
response to lipopolysaccharideATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of tumor necrosis factor productionATP-binding cassette sub-family C member 8Homo sapiens (human)
response to insulinATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of potassium ion transportATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of insulin secretionATP-binding cassette sub-family C member 8Homo sapiens (human)
neuromuscular processATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of glial cell proliferationATP-binding cassette sub-family C member 8Homo sapiens (human)
glutamate secretion, neurotransmissionATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of neuroblast migrationATP-binding cassette sub-family C member 8Homo sapiens (human)
cellular response to organic substanceATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
inorganic cation transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of uterine smooth muscle relaxationATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of tight junction disassemblyATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of blood-brain barrier permeabilityATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion import across plasma membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
action potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to hypoxiaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to ischemiaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ventricular cardiac muscle tissue developmentATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
glucose metabolic processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
apoptotic processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
determination of adult lifespanATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to xenobiotic stimulusATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to estradiolATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to ATPATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to testosteroneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
negative regulation of insulin secretionATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of insulin secretionATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
nervous system processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
CAMKK-AMPK signaling cascadeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to nicotineATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to glucose stimulusATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to tumor necrosis factorATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inorganic cation transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
positive regulation of protein localization to plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to resveratrolATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion import across plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of monoatomic ion transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
cytokine activityNicotinamide phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingNicotinamide phosphoribosyltransferaseHomo sapiens (human)
nicotinamide phosphoribosyltransferase activityNicotinamide phosphoribosyltransferaseHomo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
sulfonylurea receptor activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ADP bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
transmembrane transporter bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
voltage-gated potassium channel activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
protein bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATP bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ankyrin bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
heat shock protein bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
transmembrane transporter bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (41)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytosolNicotinamide phosphoribosyltransferaseHomo sapiens (human)
nuclear speckNicotinamide phosphoribosyltransferaseHomo sapiens (human)
cell junctionNicotinamide phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinamide phosphoribosyltransferaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
inward rectifying potassium channelATP-binding cassette sub-family C member 8Homo sapiens (human)
synaptic vesicle membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
sarcolemmaATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion-transporting ATPase complexATP-binding cassette sub-family C member 8Homo sapiens (human)
membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
acrosomal vesicleATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
nuclear envelopeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
endosomeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inward rectifying potassium channelATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
intercalated discATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
T-tubuleATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
axolemmaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
presynaptic membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
neuronal cell bodyATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cell body fiberATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
glutamatergic synapseATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (353)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID596281Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by continuous superfusion of oxytocin in presence of 10 uM ATP-sensitive potassium channel blocker glibenclamide2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID189325Insulin secretion from rat pancreatic islets (RIS) in the presence of 16.7 mM glucose at 50 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID267976Tmax in Sprague-Dawley rat at 2 mg/kg, po or 0.5 mg/kg, iv2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID195745Residual insulin release from rat pancreatic islets at a concentration of 50 uM1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID42092Changes in potassium fluxes assessed in the glucose responsive insulin-producing murine cell line beta-TC32002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID195750Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 10 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID246920Concentration giving 50% relaxation of the 30 mM KCl-induced contraction of rat aortic rings (n=11)2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID92196concentration of drug giving a 5-fold increase of the magnitude of the current induced by Ionotropic glutamate receptor AMPA (30 uM) and measured in Xenopus Oocytes expressing Rat Cortex AMPA Receptors1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID177641Effect on contractile activity of 80 mM potassium-Depolarized rat aorta2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID249397ED50/IC50 ratio was determined2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID195748Percentage residual insulin release by the compound at 1 uM from rat pancreatic islets1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID1294392Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic rings assessed relaxation of 30 mM KCl-induced contraction2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID195733Percentage residual insulin secretion at 1 uM dose from pancreatic islets incubated in the presence of 16.7 mM glucose2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID274620Activity in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 40 mg/kg, ip after 30 mins2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID389994Vasorelaxation activity in Wistar rat thoracic aortic ring assessed as inhibition of KCl-induced contraction2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID1141746Myorelaxant activity in endothelium-free rat thoracic aorta assessed as inhibition of 30 mM of KCl-induced contraction2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID177639Effect on contractile activity of 30 mM potassium-Depolarized rat aorta incubated in the presence of 10 uM Glibenclamide2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID267949Inhibition of glucose-stimulated insulin release in Wistar rat islets2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID407861Activation of ATP-sensitive potassium channel in potassium-depolarized Wistar rat aortic rings assessed as myorelaxant activity against KCl-induced contraction2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID195187Effective dose to give 50% relaxation of the KCl induced contraction1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID407862Ratio of IC50 for inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets to ED50 for myorelaxant activity in Wistar rat aortic rings2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID728947Activation of ATP-sensitive potassium channel opening in albino rat aorta rings assessed as relaxation of KCl-induced contraction of aorta rings2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
1,4,2-Benzo/pyridodithiazine 1,1-dioxides structurally related to the ATP-sensitive potassium channel openers 1,2,4-Benzo/pyridothiadiazine 1,1-dioxides exert a myorelaxant activity linked to a distinct mechanism of action.
AID189326Residual insulin release from rat pancreatic islets incubated in the presence of an insulinotropic (16.7 uM) glucose concentration and at a 50 uM concentration of drug1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID1712308Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic islets at 1 uM incubated for 90 mins in presence of 16.7 mM glucose by radioimmunological assay relative to control2016European journal of medicinal chemistry, Oct-04, Volume: 1214-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky 'carbamate' moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion.
AID195738Inhibition of residual insulin release from rat pancreatic islets in the presence of 16.7 mM glucose at 0.1 uM concentration; Not determined2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID1294391Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed relaxation of 30 mM KCl-induced contraction2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID1294397Inhibition of glucose-induced insulin secretion from Wistar rat pancreatic islets assessed as residual insulin release at 1 uM after 90 mins by radioimmunological assay2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID195744Percent inhibition of residual insulin release from rat pancreatic islets in the presence of 16.7 mM glucose at 50 uM concentration2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID1294393Vasorelaxant activity in Wistar rat thoracic aortic rings assessed relaxation of 30 mM KCl-induced contraction in presence of KATP channel blocker glibenclamide2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID1194030Vasorelaxant activity in Wistar rat endothelium thoracic aortic ring assessed as inhibition of 30 mM KCl-induced contraction2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.
AID180910The effective dose for relaxation was measured on rat aorta rings2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID172703Maximum change in MAP in rat2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID169266Concentration for 50 percent increase of the amplitude (A50) of the postsynaptic excitatory potentials induced by electric stimulation in rat hippocampal slices1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID274625Activity in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 40 mg/kg, ip after 120 mins in presence of 5-hydroxydecanoic acid2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1141750Ratio of EC50 for myorelaxant activity in endothelium-free rat thoracic aorta presence of 1 uM of KATP channel blocker glibenclamide to EC50 for myorelaxant activity in endothelium-free rat thoracic aorta absence of KATP channel blocker glibenclamide2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID253208Effect on insulin secretion from rat pancreatic islets at 50 uM concentration (n=16)2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID267950Reduction in plasma insulin level in anaesthetized Sprague-Dawley rat at 3 mg/kg, iv2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID1194038Hyperglycemic effect in Wistar albino rat assessed as effect on blood glucose at 50 mg/kg, po2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.
AID666760Myorelaxant effect in oxytoxin-induced Wistar rat uterus smooth muscle assessed as residual contractile activity by continuous superfusion of oxytocin at 10 uM2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID176043Vasodilation effects on Wistar rat mesenteric arteries precontracted with phenylephrine2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID251164Percent efficacy for inhibition of glucose stimulated insulin release from beta TC6 cells2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.
AID231900Ratio between the D50 value and the A50 value; not determined1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID286542Activity at Kir6.2/SUR1 KATP channels expressed in HEK293 cells assessed as activation of K+ currents2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Virtual screening for novel openers of pancreatic K(ATP) channels.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID24886Half life after oral administration to Sprague-Dawley rats2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID444907Activation of human recombinant SUR1/Kir6.2 channel expressed in HEK293 cells assessed as increase in ionic current by whole cell patch clamp assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Chloro-substituted 3-alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel activators: impact of the position of the chlorine atom on the aromatic ring on activity and tissue selectivity.
AID384241Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion at 10 uM relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID44707Percentage insulin release in vitro in beta-TC6 cells2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID596292Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by bolus of oxytocin injected in superfusion system at 10 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID666761Myorelaxant effect in oxytoxin-induced Wistar rat uterus smooth muscle assessed as residual contractile activity by continuous superfusion of oxytocin at 50 uM2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID195743Percent inhibition of residual insulin release from rat pancreatic islets in the presence of 16.7 mM glucose at 10 uM concentration2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID195749Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 1 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID253017Percentage of residual insulin secretion value in the pancreatic islets of rat after treatment with the compound at 10 uM concentration2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID389989Antiischemic activity in Langendorff perfused Wistar rat assessed as ratio of ischemic area to total area at 40 mg/kg, ip2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID208996Inhibition of [3H]glibenclamide binding to HEK293 cells co-expressing human Sulfonylurea receptor SUR1 and Inward rectifier K+ channel Kir6.2 without ATP2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID195198Myorelaxant activity in rat aorta in the presence 80 mM KCL.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID197436Compound was evaluated for the inhibition of insulin release from rat islets2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.
AID195747Percentage residual insulin release by the compound at 10 uM from rat pancreatic islets1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID274621Activity in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 40 mg/kg, ip after 30 mins in presence of 5-hydroxydecanoic acid2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID267979Half life in Sprague-Dawley rat at 2 mg/kg, po2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID407863Activation of ATP-sensitive potassium channel in Wistar rat pancreatic beta islets assessed as inhibition of glucose-induced insulin secretion2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID1712310Myorelaxant activity in aortic rings isolated from Wistar rat assessed as reduction in KCl-induced contractions measured after 60 mins in presence of 80 mM KCl by force-displacement transducer2016European journal of medicinal chemistry, Oct-04, Volume: 1214-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky 'carbamate' moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion.
AID666762Myorelaxant effect in oxytoxin-induced Wistar rat uterus smooth muscle assessed as residual contractile activity by continuous superfusion of oxytocin at 100 uM2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.
AID253184Effect on insulin secretion from rat pancreatic islets at 1 uM concentration (n=15)2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID267945Inhibition of glucose-stimulated insulin release in betaTC6 cells2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID286544Inhibition of insulin release from rat INS-1E cells2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Virtual screening for novel openers of pancreatic K(ATP) channels.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID389988Cardioprotective activity in Langendorff perfused Wistar rat assessed as rate pressure product at 40 mg/kg, ip recorded after 30 mins of global ischemia followed by 120 mins of reperfusion2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID596288Inhibition of glucose induced insulin secretion from rat Pancreatic islet assessed as percentage of residual insulin release2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID249972Percent residual insulin release in rat pancreatic islets upon incubation with the compound (10 uM) at 37 degree C for 90 mins2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity.
AID189324Effect on Insulin secretion from rat pancreatic islets (RIS) in the presence of 16.7 mM glucose at 10 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID161275Binding affinity towards potassium channel of rat aorta using [3H]15 as radioligand1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.
AID1351585Induction of elastin synthesis in rat VSMC at 50 uM after 48 hrs by ELISA relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID248864Concentration required to inhibit insulin release in rat pancreatic islets by 50% upon incubation with the compound at 37 degree C for 90 mins2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity.
AID267977Oral bioavailability in Sprague-Dawley rat at 2 mg/kg, po2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID248152Potency by glucose stimulated insulin release from HEK 293 cells2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.
AID1141747Myorelaxant activity in endothelium-free rat thoracic aorta assessed as inhibition of 30 mM of KCl-induced contraction in presence of 1 uM of KATP channel blocker glibenclamide2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1294395Inhibition of glucose-induced insulin secretion from Wistar rat pancreatic islets assessed as residual insulin release at 50 uM after 90 mins by radioimmunological assay2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID267975Cmax in Sprague-Dawley rat at 2 mg/kg, po2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID42231Inhibition of Beta-cell KATP channel2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives as K(ATP) channel agonists.
AID189385Reduction in plasma insulin in 30 min post-injection in rat2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID44713Percent efficacy of compound for the in vitro inhibition of insulin release from murine beta-TC6 cells2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.
AID389993Vasorelaxation activity in Wistar rat thoracic aortic ring assessed as inhibition of KCl-induced contraction at 100 uM relative to KCl2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID1074221Binding affinity to NAMPT (2 to 491) (unknown origin) by surface plasmon resonance analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID274636Vasorelaxation activity on KCl-induced contractile tone in Wistar rat thoracic aortic ring2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID44711In vitro ability to inhibit glucose stimulated insulin release in beta-TC6 cells from rat islets2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
AID179405Concentration required to inhibit insulin release in rat2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1712309Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic islets at 10 uM incubated for 90 mins in presence of 16.7 mM glucose by radioimmunological assay relative to control2016European journal of medicinal chemistry, Oct-04, Volume: 1214-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky 'carbamate' moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion.
AID274624Activity in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 40 mg/kg, ip after 120 mins2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID194548Compound is evaluated for the effect on Oxytocin-Induced contractions of rat uterus at 50 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID195201In vitro inhibition of 30 mM KCl-induced contraction of rat aorta rings.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID274633Ischemia-injured area relative to total area in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 40 mg/kg, ip in presence of 5-hydroxydecanoic acid2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID194546Compound is evaluated for the effect on Oxytocin-Induced contractions of rat uterus at 100 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1558520Inhibition of 15 mM glucose-mediated increase in intracellular Ca2+ level in mouse MIN6-c4 cells at 30 uM by FLIPR assay relative to control2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
AID286543Repolarization of tolbutamide-depolarized beta-TC3 cells2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Virtual screening for novel openers of pancreatic K(ATP) channels.
AID195734Percentage residual insulin secretion at 10 uM dose from pancreatic islets incubated in the presence of 16.7 mM glucose2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID29349pKa value determined at pH 7.42003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID267948Repolarization of HEK293 cells expressing Kir6.2/SUR1 KATP channels2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID1141748Myorelaxant activity in endothelium-free rat thoracic aorta assessed as inhibition of 30 mM of KCl-induced contraction in presence of 10 uM of KATP channel blocker glibenclamide2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID175393Concentration for 50 percent increase of the duration (D50) of the postsynaptic excitatory potentials induced by electric stimulation in rat hippocampal slices1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID44714In vitro inhibition of insulin release from murine beta-TC6 cells2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1074215Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay in presence of nicotinamide mononucleotide2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID1436475Inhibition of CLK mediated SF3B1 activation in human SK-MEL-2 cells assessed as MDM2-pre mRNA exon skipping at 10 uM after 4 hrs by luciferase reporter gene assay relative to control2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID596282Dissociation constant, pKa of the compound2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID44708Ability to inhibit the release of insulin from the mouse beta-TC6 cell line2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID596280Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by continuous superfusion of oxytocin in absence ATP-sensitive potassium channel blocker glibenclamide2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID452149Channel opening activity at KATP channel in Wistar rat pancreatic islets assessed as glucose-induced residual insulin secretion at 1 uM after 90 mins by radioimmunology2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID1194037Activation of ATP-sensitive potassium channel in Wistar rat pancreatic islets assessed as inhibition of 16.7 mM of glucose-induced insulin secretion by measuring residual insulin secretion at 10 uM after 90 mins relative to control2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.
AID728950Myorelaxant activity in albino rat aorta rings assessed as relaxation of KCl-induced contraction of aorta rings in presence of 10 uM KATP channel blocker glibenclamide2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
1,4,2-Benzo/pyridodithiazine 1,1-dioxides structurally related to the ATP-sensitive potassium channel openers 1,2,4-Benzo/pyridothiadiazine 1,1-dioxides exert a myorelaxant activity linked to a distinct mechanism of action.
AID596291Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by bolus of oxytocin injected in superfusion system at 50 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID728949Myorelaxant activity in albino rat aorta rings assessed as relaxation of KCl-induced contraction of aorta rings in presence of 1 uM KATP channel blocker glibenclamide2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
1,4,2-Benzo/pyridodithiazine 1,1-dioxides structurally related to the ATP-sensitive potassium channel openers 1,2,4-Benzo/pyridothiadiazine 1,1-dioxides exert a myorelaxant activity linked to a distinct mechanism of action.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID195191Relaxation of phenylephrine precontracted rat isolated aorta rings.2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID44576Ability to repolarize beta-TC3 cell membrane potential2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
AID247947Concentration required for 50% inhibition of insulin release in rat pancreatic B-cells2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID596290Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by bolus of oxytocin injected in superfusion system at 100 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID748042Activation of ATP-sensitive potassium channel in Wistar rat pancreatic islets assessed as reduction in high glucose-induced insulin secretion at 80 uM after 1 hr by radioimmunoassay in presence of glibenclamide2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
1,4-Benzothiazine ATP-sensitive potassium channel openers: modifications at the C-2 and C-6 positions.
AID596286Inhibition of glucose induced insulin secretion from rat Pancreatic islet assessed as percentage of residual insulin release at 1 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID195221Percentage of residual contractile response in isolated rat aorta; +++ indicates that a maximal vasorelaxant activity was observed at 500 uM1996Journal of medicinal chemistry, Feb-16, Volume: 39, Issue:4
3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.
AID177638Effect on contractile activity of 30 mM potassium-Depolarized rat aorta incubated in the absence of Glibenclamide2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID177640Effect on contractile activity of 30 mM potassium-Depolarized rat aorta incubated in the presence of 1 uM Glibenclamide2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID437030Cardioprotective effect in Langendorff perfused isolated rat hearts assessed as reduction in ischemic injury2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Predictive models, based on classification algorithms, for compounds potentially active as mitochondrial ATP-sensitive potassium channel openers.
AID748043Activation of ATP-sensitive potassium channel in Wistar rat pancreatic islets assessed as reduction in high glucose-induced insulin secretion at 80 uM after 1 hr by radioimmunoassay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
1,4-Benzothiazine ATP-sensitive potassium channel openers: modifications at the C-2 and C-6 positions.
AID195752Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 50 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID590057Anti-ischemic activity against ischemia/reperfusion-induced rat H9c2 cell death assessed as cell viability at 100 uM (Rbv = 63 +/- 2%)2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis and biological evaluation of 5-membered spiro heterocycle-benzopyran derivatives against myocardial ischemia.
AID252258Ratio of EC50 required to relax KCl induced rat aorta ring contractions to that of IC50 required to inhibit insulin release in rat pancreatic islets2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1294396Inhibition of glucose-induced insulin secretion from Wistar rat pancreatic islets assessed as residual insulin release at 10 uM after 90 mins by radioimmunological assay2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID407859Activation of ATP-sensitive potassium channel in Wistar rat pancreatic beta islets assessed as glucose-induced residual insulin secretion at 50 uM relative to control2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID79039In vitro inhibition electrically stimulated guinea pig ileum segment contraction.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID267944Repolarization of beta-TC3 cells2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID1074220Aqueous solubility of the compound after 24 hrs by LC/CLND analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID1351586Induction of elastin synthesis in rat VSMC at 20 uM after 48 hrs by ELISA2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID195742Percent inhibition of residual insulin release from rat pancreatic islets in the presence of 16.7 mM glucose at 1 uM concentration2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID175687Effective concentration required for relaxation of rat aorta rings2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID452148Channel opening activity at KATP channel in Wistar rat pancreatic islets assessed as glucose-induced residual insulin secretion at 10 uM after 90 mins by radioimmunology2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID1074217Antiproliferative activity against human A2780 cells after 72 hrs by sulforhodamine B assay2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID247873Inhibitory concentration against rat vascular smooth muscle tissue2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID267978Clearance in Sprague-Dawley rat at 2 mg/kg, po or 0.5 mg/kg, iv2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID195359Effective dose required for relaxation of the 30 mM KCl-induced contraction of rat aortic rings2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID728948Myorelaxant activity in albino rat aorta rings assessed as relaxation of 30 mM KCl-induced contraction of aorta rings2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
1,4,2-Benzo/pyridodithiazine 1,1-dioxides structurally related to the ATP-sensitive potassium channel openers 1,2,4-Benzo/pyridothiadiazine 1,1-dioxides exert a myorelaxant activity linked to a distinct mechanism of action.
AID267951Reduction in plasma insulin level in po dosed Zucker obese rat after 2 hrs2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID366927Cardioprotective effect in Langendorff perfused Wistar rat hearts assessed as ratio for ischemic injured area to total area at 40 mg/kg, ip2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Enantioselectivity in cardioprotection induced by (S)- (-)-2,2-dimethyl-N-(4'-acetamido-benzyl)-4-spiromorpholone-chromane.
AID1141751Ratio of EC50 for myorelaxant activity in endothelium-free rat thoracic aorta presence of 10 uM of KATP channel blocker glibenclamide to EC50 for myorelaxant activity in endothelium-free rat thoracic aorta absence of KATP channel blocker glibenclamide2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID248136Concentration required for inhibition of glucose stimulated insulin release from beta TC6 cells2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.
AID253196Effect on insulin secretion from rat pancreatic islets at 10 uM concentration (n=16)2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID233236Estimated selectivity ratio of ED50 and IC50 in rat was calculated2003Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID95325Maximum activation of human KATP (SUR1/Kir6.2) channel expressed in Xenopus oocytes2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
3-trifluoromethyl-4-nitro-5-arylpyrazoles are novel K(ATP) channel agonists.
AID249971Percent residual insulin release in rat pancreatic islets upon incubation with the compound (1 uM) at 37 degree C for 90 mins2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID194547Compound is evaluated for the effect on Oxytocin-Induced contractions of rat uterus at 10 uM2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID95326Percent maximal agonist response of human KATP (SUR1/Kir6.2) channel expressed in Xenopus oocytes2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
3-trifluoromethyl-4-nitro-5-arylpyrazoles are novel K(ATP) channel agonists.
AID236597Ionization constant was determined2005Journal of medicinal chemistry, May-19, Volume: 48, Issue:10
Effect on K(ATP) channel activation properties and tissue selectivity of the nature of the substituent in the 7- and the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides.
AID195199Myorelaxant activity in rat aorta with 1 uM glibenclamide and 30 mM KCL2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID1194033Vasorelaxant activity in Wistar rat thoracic aortic ring assessed as inhibition of 80 mM KCl-induced contraction2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.
AID76811Inhibition of electrically stimulated contractions of guinea pig ileum segments.2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1194036Activation of ATP-sensitive potassium channel in Wistar rat pancreatic islets assessed as inhibition of 16.7 mM of glucose-induced insulin secretion by measuring residual insulin secretion at 50 uM after 90 mins relative to control2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.
AID1194032Vasorelaxant activity in Wistar rat thoracic aortic ring assessed as inhibition of KCl-induced contraction in presence of glibenclamide2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.
AID1194047Activation of ATP-sensitive potassium channel in vascular smooth muscle cells (unknown origin) assessed as increase in elastin production at 50 uM after 48 hrs by ELISA2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design and synthesis of new potassium channel activators derived from the ring opening of diazoxide: study of their vasodilatory effect, stimulation of elastin synthesis and inhibitory effect on insulin release.
AID267947Relaxation of precontracted Wistar rat aorta rings2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID157523The percentage of residual insulin release at 50 uM of compound in the presence of glucose on rat pancreatic beta cells2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID452150Channel opening activity at KATP channel in Wistar rat endothelium-denuded aortic ring assessed as relaxation of KCl-induced contraction2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID389992Cardioprotective activity in Langendorff perfused Wistar rat assessed as rate pressure product at 40 mg/kg, ip recorded after 30 mins of ischemia followed by 120 mins of reperfusion in presence of 5-hydroxydecanoic acid2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID590054Anti-ischemic activity against ischemia/reperfusion-induced rat H9c2 cell death assessed as cell viability at 100 uM in presence of mito-KATP channel blocker 5-hydroxydecanoic acid2011European journal of medicinal chemistry, Mar, Volume: 46, Issue:3
Synthesis and biological evaluation of 5-membered spiro heterocycle-benzopyran derivatives against myocardial ischemia.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID274632Ischemia-injured area relative to total area in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 40 mg/kg, ip2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID1074219Apparent permeability from apical to basolateral side in MDCK cells at 10 uM by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID25098Acid dissociation constant was determined2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives as K(ATP) channel agonists.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID384242Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion at 1 uM relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID92192Concentration of drug giving a 2-fold increase of the magnitude of the current induced by Ionotropic glutamate receptor AMPA (30 uM) and measured in Xenopus Oocytes expressing Rat Cortex AMPA Receptors1998Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16
4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic aci
AID246525Concentration required to relax KCl induced rat aorta ring contractions by 50% upon incubation with the compound at 37 degree C for 90 mins2005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity.
AID14000Oral bioavailability in rat (Sprague-Dawley)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID666758Inhibition of glucose-induced insulin secretion from Wistar rat pancreatic islet assessed as residual insulin release at 50 uM after 90 mins by radiometric analysis2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells.
AID596285Inhibition of glucose induced insulin secretion from rat Pancreatic islet assessed as percentage of residual insulin release at 10 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID286541Activity at Kir6.2/SUR1 KATP channels expressed in HEK293 cells assessed as repolarization of tolbutamide-induced membrane depolarization2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Virtual screening for novel openers of pancreatic K(ATP) channels.
AID407860Activation of ATP-sensitive potassium channel in Wistar rat pancreatic beta islets assessed as glucose-induced residual insulin secretion at 10 uM relative to control2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID366925Cardioprotective effect in Langendorff perfused Wistar rat hearts assessed as ischemic damage measured by rate-pressure product-120 at 40 mg/kg, ip2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Enantioselectivity in cardioprotection induced by (S)- (-)-2,2-dimethyl-N-(4'-acetamido-benzyl)-4-spiromorpholone-chromane.
AID267952Displacement of [3H]glibenclamide from human Kir6.2/SUR1 expressed in HEK293 cells2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID196958Myorelaxant activity as percentage residual contractile activity in rat uterus at 50 uM concentration.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID267953Displacement of [3H]glibenclamide from human Kir6.2/SUR1 expressed in HEK293 cells in presence of 2 mM ATP2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID44709In vitro efficacy to inhibit glucose stimulated insulin release in beta-TC6 cells from rat islets2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release.
AID274637Vasorelaxation activity on KCl-induced contractile tone in Wistar rat thoracic aortic ring at 100 uM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID384245Ratio of IC50 for glucose-induced insulin secretion in Wistar rat pancreatic beta islets to EC50 for myorelaxant activity in Wistar rat aorta rings2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID596289Myorelaxant effect in KCl-induced precontracted rat aorta ring VSMC2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID384244Myorelaxant activity in potassium depolarized Wistar rat aorta rings assessed as relaxation of KCl-induced contraction2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID195192In vitro ability to relax phenylephrine contracted rat aorta rings2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID228165Vasorelaxant activity expressed as negative logarithm of the concentration causing a 50% inhibition of spontaneous myogenic activity in rat portal vein.1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.
AID188883Maximum reduction in plasma insulin in rat2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID195735In vitro percentage residual insulin secretion at 50 uM dose from rat pancreatic islets incubated in the presence of 16.7 mM glucose.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID274628LDH release in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 40 mg/kg, ip after 120 mins2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID196957Myorelaxant activity as percentage residual contractile activity in rat uterus at 10 uM concentration.2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID728946Activation of ATP-sensitive potassium channel opening in albino rat pancreatic islets assessed as inhibition of glucose-induced insulin release measured as residual insulin release at 10 uM after 90 mins by radioimmunoassay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
1,4,2-Benzo/pyridodithiazine 1,1-dioxides structurally related to the ATP-sensitive potassium channel openers 1,2,4-Benzo/pyridothiadiazine 1,1-dioxides exert a myorelaxant activity linked to a distinct mechanism of action.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID247010Myorelaxant activity of the compound against insulin secretion in the pancreatic islets ofrat; (activity expressed as ED50)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID195753Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 500 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1074218Clearance in human liver microsomes at 1 uM up to 60 mins by LC-MS/MS analysis2014Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
AID1873662Antiangiogenic activity in HUVEC cells assessed as inhibition of VEGF-induced cell proliferation at 20 uM incubated for 48 hrs by MTT assay relative to control2022Bioorganic & medicinal chemistry, 08-01, Volume: 67Chlorinated benzothiadiazines inhibit angiogenesis through suppression of VEGFR2 phosphorylation.
AID42232Percentage of maximal agonistic response of Beta-cell KATP channel as compared to diazoxide (50 uM)2002Bioorganic & medicinal chemistry letters, Oct-21, Volume: 12, Issue:20
Synthesis and evaluation of 7-substituted-3-cyclobutylamino-4H-1,2,4-benzothiadiazine-1,1-dioxide derivatives as K(ATP) channel agonists.
AID248509inhibitory concentration required for repolarization of beta cell membrane potential in presence of 10 mM glucose2004Bioorganic & medicinal chemistry letters, Dec-06, Volume: 14, Issue:23
2-(4-Methoxyphenoxy)-5-nitro-N-(4-sulfamoylphenyl)benzamide activates Kir6.2/SUR1 K(ATP) channels.
AID384243Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID1141745Inhibition of glucose-induced insulin secretion in rat pancreatic islets assessed as residual insulin release level at 10 uM preincubated for 30 mins measured after 90 mins radioimmunology analysis2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID195200Myorelaxant activity in rat aorta with 10 uM glibenclamide and 30 mM KCL2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.
AID1141749Myorelaxant activity in endothelium-free rat thoracic aorta assessed as inhibition of 80 mM of KCl-induced contraction2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID596283Myorelaxant effect in Wistar rat uterus smooth muscle assessed as inhibition of contractions induced by continuous superfusion of oxytocin in presence of 1 uM ATP-sensitive potassium channel blocker glibenclamide2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID274629LDH release in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 40 mg/kg, ip after 120 mins in presence of 5-hydroxydecanoic acid2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID195751Inhibition of insulin release from rat pancreatic islets incubated in the presence of glucose (16.7 nM) at concentration of 100 uM1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
3-(Alkylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers?
AID176359Concentration giving 50% relaxation of the 30 mM KCL-induced contraction of rat aorta rings2000Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8
3-Alkylamino-4H-pyrido[2,3-e]-1,2,4-thiadiazine 1,1-dioxides structurally related to diazoxide and pinacidil as potassium channel openers acting on vascular smooth muscle cells: design, synthesis, and pharmacological evaluation.
AID596284Inhibition of glucose induced insulin secretion from rat Pancreatic islet assessed as percentage of residual insulin release at 50 uM2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Impact of the nature of the substituent at the 3-position of 4H-1,2,4-benzothiadiazine 1,1-dioxides on their opening activity toward ATP-sensitive potassium channels.
AID779482Activation of Kir6.2/SUR1 in rat pancreatic islets assessed as residual glucose-induced insulin release at 10 uM relative to control2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
Triphenylphosphonium salts of 1,2,4-benzothiadiazine 1,1-dioxides related to diazoxide targeting mitochondrial ATP-sensitive potassium channels.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID10710Area under the MAP curve measured over 5 min.2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID44578In vitro membrane potential on murine beta-TC3 cells2001Bioorganic & medicinal chemistry letters, Jul-09, Volume: 11, Issue:13
Phenylcyanoguanidines as inhibitors of glucose-induced insulin secretion from beta cells.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID267946Inhibition of glucose-stimulated insulin release in beta-TC6 cells at 10 uM2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID728951Myorelaxant activity in albino rat aorta rings assessed as relaxation of 80 mM KCl-induced contraction of aorta rings2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
1,4,2-Benzo/pyridodithiazine 1,1-dioxides structurally related to the ATP-sensitive potassium channel openers 1,2,4-Benzo/pyridothiadiazine 1,1-dioxides exert a myorelaxant activity linked to a distinct mechanism of action.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID179966Inhibition of glucose-stimulated insulin release from Wistar rat islets2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID208997Inhibition of [3H]glibenclamide binding to HEK293 cells co-expressing human Sulfonylurea receptor SUR1 and Inward rectifier K+ channel Kir6.2 at low affinity state with 2 mM MgATP2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1294394Vasorelaxant activity in Wistar rat thoracic aortic rings assessed relaxation of 80 mM KCl-induced contraction2016European journal of medicinal chemistry, Jun-10, Volume: 115Synthesis, characterization and biological evaluation of benzothiazoles and tetrahydrobenzothiazoles bearing urea or thiourea moieties as vasorelaxants and inhibitors of the insulin releasing process.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1346625Mouse Kir6.1 (Inwardly rectifying potassium channels)1997The Journal of physiology, Mar-15, Volume: 499 ( Pt 3)Sulphonylurea receptor 2B and Kir6.1 form a sulphonylurea-sensitive but ATP-insensitive K+ channel.
AID1346573Mouse Kir6.2 (Inwardly rectifying potassium channels)1995Science (New York, N.Y.), Nov-17, Volume: 270, Issue:5239
Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.
AID1346630Rat Kir6.2 (Inwardly rectifying potassium channels)1996The Journal of biological chemistry, Oct-04, Volume: 271, Issue:40
A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,792)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901208 (43.27)18.7374
1990's411 (14.72)18.2507
2000's656 (23.50)29.6817
2010's419 (15.01)24.3611
2020's98 (3.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.30 (24.57)
Research Supply Index8.01 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index128.39 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (71.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials86 (2.94%)5.53%
Reviews192 (6.57%)6.00%
Case Studies287 (9.82%)4.05%
Observational5 (0.17%)0.25%
Other2,353 (80.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (26)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects Without Diabetes Mellitus Having Very High Fasting Triglyceride Levels, Wi [NCT01211847]Phase 244 participants (Actual)Interventional2010-10-31Completed
A Dose Titration Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension [NCT02034071]Phase 1/Phase 213 participants (Actual)Interventional2014-04-30Completed
A Multiple-Dose Pharmacokinetic Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Subjects With Elevated Fasting Triglyceride Levels [NCT01211860]Phase 19 participants (Actual)Interventional2010-10-31Completed
A Randomized, Open-label, Multi-dose Crossover Study Assessing the Pharmacokinetic Profiles of Diazoxide Choline Coated Versus Uncoated Formulations in Healthy Volunteers [NCT00688857]Phase 112 participants (Anticipated)Interventional2008-05-31Completed
An Open-Label Study to Assess the Preliminary Efficacy and Safety of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients With Genetic Obesities [NCT05532020]Phase 230 participants (Anticipated)Interventional2023-01-31Not yet recruiting
The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients [NCT03685773]Phase 20 participants (Actual)Interventional2019-04-21Withdrawn(stopped due to "Permanently terminated due to COVID-19 given the poor vaccine penetrance in liver transplant recipients.~This is not a suspension of IRB approval.")
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide [NCT03566511]Phase 224 participants (Actual)Interventional2018-06-12Suspended(stopped due to Temporarily paused while the MR center develops newer study techniques. We might resume; this is not a suspension of IRB approval.)
Combined Diazoxide and Metformin Therapy in Children With Hypothalamic Obesity Secondary to Craniopharyngioma: A Pilot Study [NCT00892073]Phase 29 participants (Actual)Interventional2006-05-31Completed
A Randomized, Open-Label, Single- and Multiple-Dose, Four-Way Parallel Study Comparing the Fed and Fasted Pharmacokinetics of Two Dose Levels of Diazoxide Choline Controlled-Release Tablet (DCCR) in Healthy VolunteersVOLUNTEERS [NCT00901823]Phase 10 participants (Actual)Interventional2011-03-31Withdrawn(stopped due to Did not support the planned development of DCCR in the new indication)
Determination if Direct Inhibition of Insulin Release With Diazoxide Decreases Renal Clearance of D-Chiroinositol (DCI) and Increases Circulating DCI in Obese Women With Polycystic Ovary Syndrome (PCOS) [NCT00683774]21 participants (Actual)Interventional2005-11-30Completed
Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF) [NCT03608163]Phase 417 participants (Actual)Interventional2018-08-10Active, not recruiting
Acute Local Ischemic Preconditioning in Patients With Type 1 Diabetes in Vivo [NCT00184821]20 participants Observational2004-06-30Completed
Diazoxide-mediated Insulin Suppression in Hyperinsulinemic Obese Men, Part III [NCT00631033]Phase 251 participants (Actual)Interventional2008-07-31Completed
A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects [NCT00696475]Phase 280 participants (Anticipated)Interventional2008-06-30Completed
Use for Diazoxide in the Initial Management of Hypoglycemia in Infants of Diabetic Mothers and Infants Large for Gestation [NCT00994149]Phase 2/Phase 3100 participants (Anticipated)Interventional2009-10-31Not yet recruiting
Use of Diazoxide in Acute Hypoglycaemia [NCT01488136]Phase 412 participants (Actual)Interventional2012-01-31Completed
A 5 Treatment Period Crossover Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR) [NCT02893618]Phase 232 participants (Anticipated)Interventional2017-07-31Not yet recruiting
Regulation of Endogenous Glucose Production by Central KATP Channels [NCT03540758]Phase 260 participants (Anticipated)Interventional2018-08-01Recruiting
Role of Hyperinsulinemia in Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis: Diazoxide Pilot & Feasibility Study [NCT05729282]Phase 124 participants (Anticipated)Interventional2023-08-01Recruiting
Efficacy of 6 Months Treatment With Diazoxide at Bedtime in Preventing Beta-cell Demise in Newly Diagnosed Type 1 Diabetes [NCT00131755]Phase 440 participants (Actual)Interventional2005-02-28Completed
Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men: a Dose Response Study, Part II [NCT00151684]Phase 225 participants (Anticipated)Interventional2004-11-30Completed
Clinical Assessment of the Treatment With Diazoxide in Children Suffering From Obesity and Hyperinsulinemia Secondary to Surgery of Hypothalamic-pituitary Lesions [NCT00306683]Phase 340 participants (Actual)Interventional2006-04-30Completed
A Randomized Placebo Controlled Single Center Phase 1 Study to Evaluate Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass [NCT04830982]Phase 10 participants (Actual)Interventional2023-09-01Withdrawn(stopped due to Withdrawn in IRB.)
A Pathophysiological Study to Determine if Enhancing Glutamate Transporter Function Produces Antidepressant Effects in Patients With Major Depressive Disorder [NCT02049385]Phase 1/Phase 210 participants (Actual)Interventional2014-01-03Terminated(stopped due to Severe side effects & lack of target engagement)
Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor [NCT02779257]Phase 40 participants (Actual)Interventional2016-04-30Withdrawn(stopped due to Subject passed away prior to enrollment)
Central Mechanisms That Regulate Glucose Metabolism in Humans [NCT01028846]Phase 410 participants (Anticipated)Interventional2011-05-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00683774 (2) [back to overview]Level of Circulating D-chiro Inositol (DCI)
NCT00683774 (2) [back to overview]Renal Clearance of D-chiroinositol (DCI) at 12 Days
NCT02049385 (1) [back to overview]MADRS Change at Day 7

Level of Circulating D-chiro Inositol (DCI)

Measured circulating concentration of plasma DCI following inhibition of insulin release using diazoxide (NCT00683774)
Timeframe: 12 days

Interventionnmol/mL (Mean)
PCOS Subjects0.27
Normal Subjects0.27

[back to top]

Renal Clearance of D-chiroinositol (DCI) at 12 Days

Following inhibition of insulin release using diazoxide, measured renal clearance of D-chiro inositol (DCI) via urinary Chiro-inositol dci assay (NCT00683774)
Timeframe: 12 days

Interventionml/min (Mean)
PCOS Subjects4.75
Normal Subjects5.16

[back to top]

MADRS Change at Day 7

Change in Montgomery Asberg Depression Rating Scale (MADRS) from baseline to 7 days post-treatment. The range of values is from 0 - 60, with a higher score indicating increased depressive symptoms. A score of 7-19 indicates mild depression; 20-34 indicates moderate depression; >34 indicates severe depression. (NCT02049385)
Timeframe: 7 days

Interventionpercentage of change in units of scale (Median)
Diazoxide0
Placebo10

[back to top]